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 ABSTRACT 
 
 
Alzheimer’s disease (AD) is the most common cause of dementia, followed by 
cerebrovascular disease (CVD). The two diseases occur together in ~20% of the demented 
population. AD and CVD share two risk factors: elevated plasma homocysteine (Hcy) and 
apolipoprotein E (ApoE) genotype.  
 
The aim of this study was to investigate the possible mechanism by which Hcy and ApoE 
may interact to alter cell cycle kinetics and neuronal physiology, potentially leading to the 
development of AD-related pathology.  
 
Using brain samples and clinical data collected from 252 patients (including preclinical, mild 
and severe AD patients and control patients) we investigated the effect of elevated levels of 
Hcy and ApoE genotype on cognitive deficit and AD-related pathology. Furthermore, using 
retinonic acid induced differentiated SH-SY5Y human neuroblastoma cells we investigated 
the effects of Hcy and ApoE isoforms on AD-related protein expression, cell proliferation, 
cell survival and the methylation pattern of cell cycle regulatory genes.  
 
The results from this study suggest that (i) Hcy affects the development of AD at multiple 
levels, cell cycle regulation, DNA methylation, induction of oxidative stress and direct effect 
on AD-type protein accumulation and (ii) these effects are modulated by the ApoE genotype. 
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1. INTRODUCTION 
 
1.1. Alzheimer's Disease 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease; the gradual 
cognitive decline is the main clinical feature of the disease. In the early stages of AD, patients 
present with mild cognitive impairments (MCI) such as amnesia which can initially be 
mistaken for normal age-related memory loss. As the disease progresses, the memory 
problems become more severe and interfere with daily living. Individuals develop aphasia 
(language impairment) and apraxia (impairment in the co-ordination of fine movements). At 
late stages psychosis and personality changes are also very common
195
. 
In a study carried out in 2006, the Delphi consensus
1
, it was estimated that at the time there 
were 24.3 million people with dementia, of which half were considered to have AD. It is 
predicted that the number of new cases will double in the next 20 years
1
. The duration of the 
disease from onset of symptoms ranges from 5 to 10 years
195
. Given the duration of the 
disease and the long term care required, there is a heavy social and economical burden placed 
on family, carers and healthcare services. The development of diagnostic tests and therapeutic 
interventions is crucial for this most devastating disease. 
 
1.1.1. Alzheimer's Disease Pathology 
 
AD has two distinct pathological features that present in the brain; these are neurofibrillary 
tangles (NFT) and senile plaques (SP)
118, 195
. The NFT are composed of intracellular paired 
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helical filaments (PHF) formed from hyperphosphorylated microtubule-associated protein, 
tau
115
. Tau pathology eventually leads to loss of synapses and neuronal death as intracellular 
trafficking is disrupted
116, 134
. The plaques are composed of extracellular deposits of β-
amyloid (Aβ) formed from the cleavage of amyloid precursor protein (APP). It is debatable 
whether the presence of plaques correlates with increase cell death
114
. These pathological 
processes contribute to loss of synapses and neuronal networks, leading to brain atrophy and 
dementia.  
 
1.1.2. Cell Cycle Theory  
 
In recent years, the cell cycle theory has gained popularity in AD research
2
. It is hypothesised 
that AD is caused by a re-activation of the cell cycle in aging differentiated neurones. In 
neurones of healthy elderly individuals, the neuronal entry into the cell cycle is followed by 
the activation of cell cycle regulatory mechanisms (e.g. cyclin dependent kinase inhibitors), 
which halt the progression of cell cycle and inhibit neurones from bypassing the G1/S 
transition point. In AD it is thought that neurones bypass this G1/S transition point due to a 
failure of the cell cycle regulatory mechanisms. Passed the G1/S transition point neurones are 
unable to re-differentiate. Cells replicate their DNA, but as neurones are unable to undergo 
cytokinesis, the cells remain suspended in the G2 cell phase. This leads to activation of 
aberrant intracellular mitogenic signalling resulting in upregulation of kinase activity and 
downregulation of phosphatases. This phenomena may explain the formation of both the 
tangle and plaque pathology seen in AD
2
.    
The re-activation of the cell cycle is seen in normal aging neurones and is thought to play a 
role in synaptic plasticity
3
. AD pathology is seen in regions of the brain that are associated 
with high synaptic plasticity, such as the hippocampus. This suggests that neurones that can 
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undergo synaptic plasticity are more vulnerable to aberrant mitogenic stimuli or failure in cell 
cycle regulation. The trigger that induces these neurones to leave their differentiated state and 
develop AD pathology is still unknown
3
. 
 
Figure 1 
Cell cycle theory of Alzheimer’s disease (adjusted from 2 ).   
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1.1.3. Risk Factors 
 
The study of known risk factors of AD has played an important role in exploring the 
pathogenesis of this disease. Old age is one of the risk factor best associated with AD
4
. There 
are other known risk factors that have been identified as predisposing individuals to 
developing AD; these include head trauma, hypertension, diabetes, depression, menopause 
and poor education [reviewed in 
5
and 
6
]. Furthermore, raised plasma homocysteine levels
7
 and 
vascular disease
8
 are  seen as risk factors in AD and both these risk factors will be discussed 
further on in this chapter. While specific disease causing mutations have been identified on a 
small number of genes (APP, PS1 and PS2
157
); these mutations are responsible for the 
development of AD in less than 5% of patients. In the rest of AD patients, the disease cannot 
be accounted for by a single mutation. Nevertheless, the contribution of genetic factors to the 
disease is undeniable. The best known genetic risk factor for sporadic AD is the epsilon 4 
variant of the apolipoprotein E gene (ApoE)
120
.  
 
As explained above AD is the main cause of dementia; the next leading cause is 
cerebrovascular disease (CVD), which includes stroke, carotid stenosis, and aneurysms. CVD 
alone accounts for ~16% of dementia cases, and CVD with AD makes up 20% of all dementia 
cases
191
. A number of studies have shown that the clinical symptoms of AD are more severe 
when patients have CVD, suggesting that the occurrence of the two diseases is pathogenically 
linked.  A number of CVD risk factors have been associated with AD, e.g. hypertension and 
diabetes
192
. Two other common risk factors of CVD and AD are elevated plasma Hcy levels 
and ApoE4 genotype; both are the focus of this study.  
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1.2.  Apolipoprotein E 
 
Apolipoprotein E (ApoE) is a constituent of chylomicrons and very low density lipoprotein 
(VLDL); its primary function is lipid transport and metabolism. In the central nervous system, 
ApoE is involved in various aspects of neuronal repair and neuroprotection. In the brain ApoE 
is mainly secreted by astrocytes and has a role in cholesterol homeostasis, lipid distribution to 
regenerating axons, synaptic remodelling and remyelination of schwann cells
9;10
. 
 
The ApoE gene is located on chromosome 19q13.2 and consists of 3 introns and 4 exons; 
encoding a 317 amino acid precursor protein. Following post-translational splicing a 299 
amino acid (34.2kda) ApoE glycoprotein is generated. The ApoE N-terminal domain contains 
the LDL receptor binding region (residues 1-191), while the C-terminal domain contains the 
lipid binding region (residues 222-299)
11
. The ApoE gene is polymorphic with three alleles 
(ε2, ε3, and ε4), producing three isoforms; ApoE2, ApoE3, and ApoE4. The ApoE isoforms 
differ in amino acid residues at positions 112 and 158. ApoE2 has a cysteine residue at both 
sites, ApoE3 has cysteine at 112 and arginine at 158 and ApoE4 has arginine at both sites
11
.  
Six genotypes are generated from these polymorphisms; 3 homozygous (ε2ε2, ε3ε3, ε4ε4) and 
3 heterozygous (ε2ε3, ε2ε4, ε3ε4). The polymorphisms have an influence on the levels of 
protein produced; ApoE2 levels in plasma are higher than ApoE3 and ApoE4. The differing 
amino acid residues at the two positions (i.e. 112 and 158) alter the conformation of the N-
terminal domain and influence the functionality of ApoE
12
. ApoE2 has been associated with 
hyperlipoproteinemia, which can lead to atherosclerosis and CVD. The cysteine residue at 
positions 112 and 158 in ApoE2 results in a poor binding of the N-terminal to receptor 
binding sites; this decreased binding activity of ApoE2 results in elevated cholesterol levels
13
. 
In AD the ApoE ε2 allele has be found to have a protective effect. The ApoE3 genotype is 
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common in all human populations
14, and this genotype is considered as the ‘neutral’ ApoE 
genotype in AD
15
. A large number of studies have linked ApoE4 to AD [Reviewed in 
15
]. 
There is an increased frequency of the ApoE ε4 allele in late on-set familial and sporadic AD 
patients
16
. With increasing number of ApoE ε4 alleles the risk of developing AD increases 
from 20 to 90%, the age of onset of the disease decreases from 84 to 68 years
17
 and the rate of 
cognitive decline increases
18
. These studies suggest a dosage effect of ApoE4. Post-mortem 
studies have found that ApoE ε4 carriers have significantly more neuritic plaques and tangles 
in neocortical regions of the brain compared to non-carriers
19;20
. However, the ApoE4 
genotype is only a risk factor for AD, meaning that the presence of this variant does not 
necessarily cause AD
21;22
. Furthermore, in some ethnic groups the ApoE ε4 allele has no 
association with AD
14
. These studies suggest that the ApoE4 genotype alone is neither 
necessary nor sufficient for AD development, and this risk factor may work in combination 
with other factors to have a role in the pathogenesis of AD.   
 
The mechanism by which the ApoE ε4 allele has a role in generating AD-type pathology is 
still unclear [reviewed in
23
]. However, a number of mechanisms have been postulated. These 
briefly include a direct interaction of ApoE with beta amyloid: the binding efficiency of the 
isoforms to beta amyloid was found as follows; ApoE2 > ApoE3 >> ApoE4. It has been 
suggested that ApoE has a role in the clearance of beta amyloid; and the binding efficiency of 
the different isoforms is reflected in the association of the isoforms with Aβ aggregation24 and 
senile plaque formation in AD
25
. ApoE has also been shown to have an isoform-dependent 
effect on tau phosphorylation and tangle formation
26
. The role of ApoE in lipid distribution is 
also thought to play a part in AD development
27
. Furthermore, isoform-specific effects on 
neuronal repair and synaptogenesis have also been observed
28
. 
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1.3. Homocysteine 
 
Homocysteine (Hcy) is a sulfur-containing non-essential amino acid with a free-thiol group. It 
is a metabolite of methionine formed as a byproduct of the folate cycle
29
. The diagram below 
illustrates the pathway of Hcy metabolism.  
 
 
Figure 2 
Homocysteine metabolism in the folate cycle. Hcy is an intermediate product generated 
from the demethylation of methionine. Hcy can be remethylated to methionine in the presence 
of methionine synthase and folate/vitamin B12. Hcy can also be catabolised to cysteine via the 
transsulfuration pathway, and this is dependent on cystationine beta synthase (CBS) and 
vitamin B6.   
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Methionine is converted to s-adenosyl methionine (SAM); this is the most important methyl 
donor in the body. After losing its methyl group SAM is converted to s-
adenosylhomocysteine (SAH). SAH is then hydrolysed to generate Hcy and adenosine; this is 
a reversible reaction and equilibrium favors the synthesis of SAH. Hcy can be remethylated to 
methionine in the presence of vitamin B12, folate, and 5-methyltetrahydrofolate. When 
methionine is in excess Hcy is irreversibly converted into cysteine by cystathionine β-
synthase (CBS) in the presence of vitamin B6. The distribution of Hcy depends on metabolic 
status; therefore any deficiencies in vitamins/enzymes in the pathway would lead to an 
imbalance in Hcy homeostasis and alter plasma Hcy levels
29
.  
 
Normal levels of plasma Hcy levels range between 5 to 15µmol/L. Hyperhomocysteinemia 
describes increased levels of plasma Hcy. Levels are defined as moderate (15 to 30µmol/L), 
intermediate (30 to 100µmol/L) and severe (>100µmol/L). Plasma Hcy levels increase with 
age, which may be a result of a decline in renal function
30
. The levels of Hcy in the cerebral 
spinal fluid (CSF)  is 5-30% of that of plasma
31
, suggesting that transport of Hcy in the brain 
is highly regulated, protecting the brain from increased levels of Hcy
32;33
.    
 
Elevated plasma Hcy levels have been reported in AD patients relative to controls
34;35
, and the 
levels of Hcy appear to correlate with disease progression
34;36
. AD patients with high plasma 
Hcy levels show rapid medial temporal lobe atrophy
37
, higher number of silent brain 
infarctions, and a greater rate of cognitive decline
38-40
. This relationship between Hcy and 
cognitive functioning is also seen in homocystinuria. Homocystinuria is a genetic disorder 
which causes severe hyperhomocysteinemia due to cystathionine beta-synthase deficiency. 
The main clinical symptom of homocystinuria is mental retardation, suggesting that Hcy 
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influences cognitive performance. Furthermore, in a study by Nilsson et al
41
 oral folate 
supplementation given to patients with mild to moderate dementia and elevated Hcy levels 
was found to lead to a significant improvement in cognitive performance; whereas patients 
with mild to moderate dementia and normal plasma Hcy levels showed no improvement. 
While these studies do not prove that a relatively small increase in Hcy levels causes 
cognitive deficit, it is clear that early vitamin supplementation aimed at reducing plasma Hcy 
levels may halt or at least delay cognitive decline in AD patients. This is further supported by 
the systematic review of the handful of trials into the effect of folate in the elderly
193
.     
 
Although elevated plasma Hcy is an acknowledged risk factor for AD, the mechanism by 
which it contributes to the pathogenesis of the disease is not fully understood. It has been 
suggested that Hcy may trigger β-amyloid aggregation42 and tau hyperphosphorylation43. Hcy 
has also been found to cause oxidative stress
44;45
, and is neurotoxic through its action via a 
glutamate receptor agonist
46
. Alternatively, changes in Hcy levels could induce epigenetic 
changes via altering DNA and histone methylation
47-49
. There is little doubt that excess Hcy in 
the elderly is harmful, however the role of this amino acid in AD development is still a matter 
of debate and requires further study. 
 
1.4. DNA Methylation 
 
Epigenetics describes the regulation of genomic function which is independent of the DNA 
sequence. This can include DNA methylation, histone acetylation and results in changes in 
chromatin and chromosome structure. Epigenetic modifications allow regulation of gene 
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transcription and gene expression, and therefore have a significant influence on cellular 
function. 
 
DNA methylation involves the addition of a methyl group from s-adenosyl methionine (SAM) 
to a cytosine residue on the DNA sequence. High levels of DNA methylation is found in CpG 
islands that occur close to promoter regions of a gene. This prevents binding of transcription 
factors and allows the regulation of gene expression. DNA methylation is influenced by the 
methylation potential, which refers to the ratio of metabolites in the folate cycle. As the cycle 
is influenced by dietary intake of vitamin B6, B12, folate and methionine, dietary variation 
could potentially affect DNA methylation and result in the alteration of gene expression. 
Since Hcy is an important part of the methylation cycle, dysregulation of DNA methylation 
may be one of the mechanisms by which elevated Hcy levels alter gene expression and lead 
ultimately, via the cell cycle alterations, to the degeneration of neurones in AD.       
 
1.5. Possible Interactions Between ApoE and Homocysteine 
 
Elevated plasma Hcy levels and ApoE4 genotype are common risk factors in both AD and 
CVD. A recent study suggests that the effects of plasma Hcy levels on cognitive performance 
are dependent on ApoE genotype
50
. Given that ~70% of plasma Hcy is plasma protein-bound, 
of which ~30% is lipoprotein-bound, a chemical interaction between Hcy and ApoE is a 
plausible explanation
51
. Hcy forms disulfide bonds with cysteine residues on lipoproteins
51-53
. 
Therefore, structural characteristics of the lipoproteins would influence Hcy binding. As each 
ApoE isoform has a different number of cysteine residues, they could interact differently with 
Hcy. ApoE2 has two free cysteine residues; therefore its binding capacity for Hcy would be 
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greater than that of either ApoE3 or ApoE4. The presence of ApoE2 may reduce the amount 
of free circulating Hcy, thus protecting the brain from the harmful effects of this amino acid. 
This scenario may explain the protective role of ApoE2 in AD. On the other hand, the binding 
of Hcy to ApoE could potentially result in a change in the function of the lipoprotein. In view 
of this, we hypothesise that Hcy may have a differential isoform effect on the activity of 
ApoE. 
 
Interaction between ApoE and Hcy could also occur indirectly via common signaling 
pathways (summarised in Figure 3). Hcy is a glutamate receptor agonist, acting on NMDA 
receptors, that directly increases calcium influx into neurones, activating a number of 
downstream  kinase pathways, e.g. MARK pathway
54
. Binding of ApoE to ApoE receptor 2 
(ApoER2) and VLDL receptor (VLDLR) induces tyrosine phosphorylation of Dab1 at the 
cytoplasmic domain. This leads to the activation of NMDA receptors and increases calcium 
influx into neurones (see Figure 3). ApoE also activates several signalling pathways 
(including the MARK pathway) via the LDL receptor family.  
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Figure 3 
Diagrammatic illustration of possible interactions of ApoE and Hcy [Adjusted from
55
].  
 
Chapter 1 Introduction 
 
13 
1.6. ApoE, Homocysteine and the Cell Cycle 
 
ApoE has been shown to inhibit proliferation of smooth muscle cells, mediated through cell 
cycle arrest at the G0/G1 transition point
56
. However this effect is isoforms-dependent, with 
ApoE4 shown to be less effective at inhibiting smooth muscle cell proliferation than the other 
isoforms (ApoE2 > ApoE3 > ApoE4)
57;58
. Hcy on the other hand, has been shown to stimulate 
cell proliferation. In a study also involving smooth muscle cells, high levels of Hcy induced 
increased cyclin A expression and cell proliferation
59
. However in a recent study, Hcy was 
found to inhibit endothelial cell proliferation through altering DNA methylation of the cyclin 
A promoter. This was associated with increased SAH levels, reduced activity of DNA 
methyltransferases (DNMTs) and increased histone acetylation at the promoter region
49
. 
These studies highlight the possibility that Hcy induced alterations in the methylation pattern 
of cell cycle related genes may have opposing effects in different cell types. This raises the 
possibility that in AD, the aberrant expression of cell cycle related genes is due to Hcy 
induced changes in their promoter methylation.     
 
Studies have shown that both ApoE and Hcy influence the cell cycle individually. Therefore it 
is possible that the interaction of the two risk factors, whether directly or indirectly, could 
generate a differential cell cycle response depending on the ApoE isoform.   
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2. SUMMARY OF THE RESEARCH 
PROPOSAL 
 
Alzheimer’s disease (AD) is the most common cause of dementia in the developed world, 
followed by cerebrovascular disease (CVD). The two diseases occur together in ~20% of the 
demented patient population
191
. AD and CVD share two risk factors: elevated plasma Hcy 
level and apolipoprotein E genotype. A recent study suggests that plasma Hcy level and ApoE 
genotype may not represent independent risk factors for cognitive decline. The aim of this 
project is to investigate the possible mechanism by which Hcy and ApoE may interact to alter 
neuronal physiology, potentially leading to the development of AD-related pathology. We 
plan to investigate three hypotheses.  
Hypothesis 1. Since elevated levels of plasma Hcy are a recognised risk factor for 
Alzheimer’s disease, we hypothesis that elevated levels of Hcy are associated with more 
severe pathology and cognitive deficit in Alzheimer’s disease patients.  
Hypothesis 2. We hypothesise that the effect of Hcy are dependent on the ApoE genotype.  
Hypothesis 3. We will investigate the effect that Hcy has on cell proliferation, cell survival 
and the methylation pattern of cell cycle regulatory genes. We hypothesise that Hcy 
contributes to the development of AD by affecting the neuronal cell cycle, and that the effect 
of Hcy on the cell cycle is modulated in an ApoE isoform-dependent manner. Since prior 
literature shows inconsistent and cell-type specific effects for both Hcy and ApoE we are 
unable to predict the measures of interactions (as hypothesised in Hypothesis 2 and 
Hypothesis 3).   
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3. METHODS 
  
 
3.1. Patients 
  
We used human brain tissue from the Thomas Willis brain bank (brain tissue collected by 
OPTIMA). The 206 patients included in this study (64 control patients (entorinal stage), 57 
mild AD patients (limbic stage) and 85 severe AD patients (neocortical stage)) were all 
participants of the Oxford Project to Investigate Memory and Ageing (OPTIMA) study. 
Patient numbers were not based on power calculations, but on sample availability. Without 
preliminary data on the experimental variation of different measures we could not perform 
power calculations. Patient numbers in this study are lower than most neuropathology based 
studies. The donated brain tissue is stored by the Thomas Willis brain bank, while OPTIMA 
holds the wealth of collected longitudinally clinical information. We have results of yearly 
cognitive tests (CAMCOG and MMSE) and plasma Hcy levels. The tissues collected by the 
brain bank have been characterised in detail by a consultant neuropathologist using standard 
diagnostic protocols (CERAD protocol and Braak staging for AD). The extent of the 
contribution of any vascular pathology to the clinical dementia was determined by the clinical 
neuropathologist)
192
.  
Chapter 2 Methods 
 
16 
 
3.2.  Extraction of RNA, DNA and Protein 
   
3.2.1. TRI-Reagent Method  
 
TRI Reagent
®
 is a ready-to-use reagent which allows simultaneous isolation of RNA, DNA 
and proteins from samples. 100mg of brain tissue was homogenised in 1ml TRI-reagent 
(Sigma Aldrich). The sample was incubated at room temperature for 5 minutes, and 100µl 1-
bromo-3-chloropropane was added. The solution was shaken vigorously for 15 seconds, 
incubated at room temperature for 2 minutes and centrifuged at 12,000g for 15 minutes at 
4
o
C. The mixture separated into 3 layers: a lower red phenol-chloroform phase (protein), 
interphase (DNA) and the colourless upper aqueous phase (RNA).   
 
3.2.1.1.RNA extraction 
 
The aqueous phase was transferred to a clean eppendorf tube for subsequent RNA extraction. 
The RNA was precipitated from the aqueous phase by adding 500µl isopropanol and mixed 
by inversion. The sample was stored at room temperature for 5 min, and then centrifuged at 
12,000g for 8 minutes at 4°C. The RNA pellet was washed in 1ml 75% ethanol and 
subsequently centrifuged at 7,500g for 5 minutes at 4°C. Supernatant was discarded and the 
pellet was air dried for 30 minutes at room temperature. The pellet was then dissolved in 
100µl water. The sample was treated with DNase, 1 unit per µg (Promega). RNA was re-
extracted with TRI-reagent (as described above) and sample stored at 4
o
C.   
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3.2.1.2.DNA extraction  
 
After the removal of the aqueous phase (for RNA extraction) the remaining two layers of the 
samples were centrifuged at 12,000g for 15 minutes at 4°C and any remaining aqueous phase 
was removed. The solution was mixed with 300µl of ethanol and centrifuged at 12,000g for 5 
minutes at 4
o
C to produce a DNA pellet. The supernatant was transferred to a clean tube for 
subsequent protein extraction. The DNA pellet was washed on the shaker for 1 hour in 0.1M 
sodium citrate in 10% ethanol. The sample was centrifuged at 12,000g for 5 minutes; 
supernatant discarded and washes repeated twice. The DNA pellet was then washed for 30 
minutes in 1.5ml 75% ethanol and centrifuged at 2,000g for 5 minutes. The pellet was air 
dried overnight and then dissolved in 400µl nuclease free water. DNA concentration and 
purity were measured using spectrophotometry (NanoDrop-1000 Spectrophotometer). All 
samples were diluted to a final concentration of 25ng/µl and stored at 4
o
C.   
 
3.2.1.3.Protein extraction 
 
The protein was precipitated from the supernatant as collected above by addition of 3 volumes 
acetone. After 15 minutes incubation at room temperature, the sample was centrifuged at 
12,000g for 10 minutes at 4
o
C. The supernatant was discarded and the pellet was washed three 
times in 1.2ml of 0.3M guanidine hydrochloride in 95% ethanol and 2.5% glycerol; sample 
was spun at 8,000g for 5 minutes and supernatant removed. A final wash was performed in 
1.2ml ethanol containing 2.5% glycerol; sample was again spun at 8,000g for 5 minutes. The 
protein pellet was air dried for 1 hour and dissolved in RIPA buffer (0.1M NaCl, 10mM 
TrisHCl, 1mM EDTA, 400µg/ml PMSF, 2µg/ml aprotinin and 1% SDS). Protein 
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concentration and purity were measured using spectrophotometry. All samples were diluted to 
a final 1mg/ml concentration and stored at -70
o
C. 
 
3.2.2.  DNA Extraction using QIAGEN Genomic-tips 
 
The QIAGEN Genomic-tips together with the Genomic DNA Buffer Set (Blood & Cell 
Culture DNA Maxi Kit, Qiagen) provide a reliable method for the isolation of pure high–
molecular-weight genomic DNA directly from tissue samples. The purification procedure is 
based on the selective binding of genomic DNA to the anion-exchange resin in the genomic 
tip.  
 
400mg of brain tissue (lateral temporal lobe) was homogenised and transferred to 19ml of 
Buffer G2 containing RNase A (204U) and RNAse T1 (100U). The sample was vortexed and 
incubated at 37
o
C for 30 minutes. Proteinase K (300U) was added to the sample, vortexed and 
incubated at 50
o
C for 2 hours. 
 
The Qiagen genomic tip was equilibrated with 10ml of Buffer QBT. The sample was vortexed 
for 20 seconds and applied to the equilibrated genomic tip. The genomic tip was washed twice 
with 15ml Buffer QC, and DNA was eluted with 15ml of Buffer QF (50
o
C). DNA was 
precipitated with 10.5ml of isopropanol and gently mixed. Strings of DNA were collected 
with an inoculating loop and transferred to 1ml of 70% ice-cold ethanol. The DNA was spun 
at 3000g for 20 minutes at 4
o
C, supernatant discarded, and pellet air dried overnight. The 
pellet was dissolved in 500µl nuclease free water and incubated at 55
o
C for 2 hours. DNA 
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concentration and purity were measured using spectrophotometry. The A260:A230 ratio was 
greater than 1.7 and the A260:A280 ratio was greater than 1.8. The DNA samples were stored at 
4
o
C. 
 
3.3.  Brain Homocysteine  
 
The OPTIMA study subjects have regular plasma Hcy measurements collected longitudinally. 
However the levels of Hcy in the brain are known to be quite different to that of plasma. High 
performance liquid chromatography (HPLC) with electrochemical detection (ECD) was used 
to measure levels of free Hcy in the brain samples
61
. 
 
3.3.1. Brain Tissue  
 
Occipital lobe samples were used to measure the levels of free Hcy in the brain. 10mg of 
brain tissue was homogenised in 1ml of RIPA buffer (0.1M NaCl, 10mM TrisHCl, 1mM 
EDTA, 1% protease inhibitor cocktail). The samples were spun at 13,000g for 5 minutes, and 
the supernatant collected for analysis.    
 
3.3.2. HPLC with ECD 
 
High pressure liquid chromatography coupled to electrochemical detection (HPLC-ECD) on a 
boron-doped diamond (BDD) working electrode was used for measurement of Hcy and 
methionine levels in brain tissue samples. The HPLC-ECD method was optimised from the 
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Bailey et al protocol taken from Methods in Molecular Biology
60
. The method has a high 
sensitivity and specificity as determined previously. We have not repeated the quality control 
experiments for the performance of the assay
60, 61, 196
.  
 
The HPLC system consisted of a Coulchem II Multielectrode Detector (ESA Analytical, UK), 
5021A Conditioning Cell (ESA Analytical, UK), 5014B Microdialysis Cell (Phenomenex, 
UK) and a 5040 Analytical Cell containing the BDD electrode (ESA Biosciences, UK). 
Samples were injected into the HPLC system through a 7726 Rheodyne 6-port injection valve 
(IDEX Health & Science Group, USA) using a 50µl Rheodyne 2” Syringe (SGC, USA). The 
mobile phase was pumped through the system using a 580 twin-reciprocating pump (ESA 
Analytical, UK), passing through a vacuum degasser (Shodex, USA). Data was collected and 
analysed using the Prime Data Acquisition and Reporter software (HPLC Technology, UK).         
 
The optimal operating potential for detection of Hcy and methionine on the BDD electrode 
was at 1400mV, initially a 1900mV potential was applied for 30 seconds. The mobile phase 
was composed of 25mM sodium dihydrogen phosphate (NaH2PO4), 1.4mM 1-octane sulfonic 
acid and 7% acetonitrile. All chemicals used were of HPLC electrochemical grade. How the 
mobile phase was made was crucial for HPLC-ECD as small changes would influence trace 
analysis. 3.9g NaH2PO4 and 432mg 1-octane sulfonic acid was dissolved in 800ml of polished 
deionised polished water (18.2MΩ-cm). The pH was adjusted to pH 2.65. The solution was 
made up to 1L with polished deionised water and mixed. 70ml was removed and discarded 
before 70ml of acetonitrile was added. The final solution was vacuum filtered through a 
Nylon-66 Filter (pore size 0.2µm). The flow rate of the mobile phase was set at 0.8ml/min on 
the pump.  
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To make the HPLC-ECD composite standard 100µl of 1mM homocysteine (Sigma Aldrich, 
UK) and 50µl of 1mM methionine (Sigma Aldrich, UK) were mixed and the solution made up 
to 10ml with polished deionised water. For HPLC-ECD sample preparation, supernatant (see 
3.3.1) was thawed, and 25µl added to 225µl of polished deionised water. This was vortexed 
for 30 seconds and stored on ice for 10 minutes. 250µl of 0.1M perchloric acid was added to 
the sample, vortexed for another 30 seconds before being transferred to a 3kDa cut-off 
centrifugal filter unit (Millipore, USA). The samples were centrifuged for 30 minutes at 
14,000g at 4
o
C and the filtrate stored on ice until injection.      
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3.4. ELISA 
 
3.4.1. ELISA: Quantitative protein expression studies from brain tissue 
 
ELISA (enzyme linked immunosorbant assay) was performed to measure the expression of 
proteins in the brain.  Proteins studied and the primary and secondary antibodies are listed in 
Table 1. 
 
Protein samples were thawed and diluted to 10µg/ml in 0.1M carbonate buffer (pH 9.6). Each 
sample was represented in triplicates; 100µl of diluted protein was added per well and 
incubated overnight at 4
o
C. Following the removal of the coating solution (using an Elx405 
96-well plate washer, BioTek) 200µl blocking solution (PBS containing 1%BSA) was added 
to each well and plates were incubated at room temperature for 2 hours. Blocking solution 
was removed by aspiration and 100µl of the primary antibody was added to each well and 
incubated overnight at 4°C. Following the washes with PBST (PBS/0.1% tween20), the plates 
were incubated for 2 hours at room temperature with 100µl of biotinylated secondary 
antibody. This was followed by rigorous washing and incubation in 100µl of Streptavidin-
HRP (1:200, R&D Systems). Immunoreactivity was visualized with o-phenylenediamine 
dihydrochloride (Sigma Aldrich), a peroxidase substrate. The reaction was stopped by adding 
25µl of 4M H2SO4. Absorbance was read at 490nm with a plate reader (Opsys MR
TM
 
microplate reader, Dynex). 
 
For each ELISA assay we used a calibration curve that allowed the quantification of protein in 
our samples. For the cell cycle related proteins the standard curve was prepared from a rapidly 
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dividing cell line (Flp-In™ T-Rex™ 293 cells; Invitrogen). The cells were cultured for 
several days (to attain rapid growth without reaching confluence). Protein was extracted from 
the cells using Cytobuster (Novagen) containing 1% Protease Inhibitor Cocktail (Sigma 
Aldrich). The protein standard was spun at 15,000g for 10 minutes. Supernatant was 
transferred to clean a tube and used to carry out 2-fold serial dilutions in Cytobuster 
containing 1% Protease Inhibitor Cocktail.  
 
For β-amyloid, AT8, DCII, 4-hydroxynonenal and 8-hydroxyguanosine labelling the standard 
sample for the calibration curve was derived from the brain tissue of a patient with 
Alzheimer’s disease. For NeuN labelling the standard was derived from a brain tissue sample 
from a healthy elderly individual.   
 
Data was expressed as arbitrary units obtained from the optical density measurements and the 
calibration curve which was generated from serial dilutions of the standard protein sample. 
Constructing a calibration curve on each ELISA plate allowed each measurement to be given 
an arbitrary value relative to the calibration curve (see Figure 4).  
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Table 1  
List of proteins studied and the concentration of primary/secondary antibodies used for 
ELISAs. 
 
Protein Measured 
Primary Antibody 
Concentration 
Secondary Antibody 
Concentration 
Mouse monoclonal 
amyloid-β 
1:5000, Dako Biotinylated polyclonal rabbit anti-
mouse immunoglobulin (1:2000, Dako) 
Mouse monoclonal 
PHF-Tau, AT8 
1:1000, Innogenetics Biotinylated polyclonal rabbit anti-
mouse immunoglobulin (1:2000, Dako) 
Mouse monoclonal 
Alzheimer’s disease 
tau, DCII 
1:500, Sigma Aldrich Biotinylated polyclonal rabbit anti-
mouse immunoglobulin (1:2000, Dako) 
Goat polyclonal 8-
hydroxyguanosine 
1:2000, AbD Serotec Biotinylated polyclonal rabbit anti-goat 
immunoglobulins (1:2000, Dako) 
Goat polyclonal 4-
hydroxynonenal 
1:4000, Abcam Biotinylated polyclonal rabbit anti-goat 
immunoglobulins (1:2000, Dako) 
Mouse monoclonal 
neuronal nuclei, 
NeuN 
1:1000, Chemicon Biotinylated polyclonal rabbit anti-
mouse immunoglobulin (1:2000, Dako) 
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Figure 4 
ELISA Calibration Curve. (x-axis - optical density measurements, y-axis - standard protein 
sample concentration, µg/ml) 
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3.5. DNA Methylation 
 
3.5.1. % Global of DNA Methylation 
 
Global DNA Methylation from DNA extracted from the lateral temporal lobe was measured 
by HPLC by our collaborators in Leicester University. See Sandhu J et al, 2009 for the 
method used
61
.  
 
3.5.2. Methylation Status of CDKIs  
 
Custom-made Methyl-Profiler DNA Methylation PCR Arrays were purchased from 
SABiosciences. The Arrays allow simultaneous profiling of DNA methylation of five CDKI 
gene promoter regions (p16
INK4a
, p15
INK4b
, p27
kip1
, p21
cip1
and p57
kip2
).  
 
Using the Methyl-Profiler™ Arrays and PCR primers together with the DNA Methylation 
Enzyme Kit we can analyse the methylation status of CpG islands in the promoter region of 
CDKI genes. Four digests (Mo, Ms, Md, Msd - see Figure 5) were set up to detect different 
methylated DNA fractions using real-time PCR. The product of a mock digest (Mo) contained 
all of the input genomic DNA. The product of the methylation-sensitive (Ms) restriction 
enzyme (Enzyme A) digest contained hypermethylated DNA sequences, while the product of 
the methylation-dependent (Md) restriction enzyme (Enzyme B) digest contained 
unmethylated DNA sequences. And finally the product of a double digest (Msd) measured the 
background and the success of both enzymatic digestions.  
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Figure 5 
Using DNA Methylation Enzymes (i.e. Enzyme A and Enzyme B) can set up four reactions to 
detect different methylated DNA fractions using real-time PCR. 
 
Chapter 2 Methods 
 
28 
Using the two digestion enzymes (i.e. Enzyme A and Enzyme B), four digests are performed 
to detect different DNA methylation fractions. We prepared the four restriction digest as 
following (see Table 2). 
 
Table 2 
Setting up four restriction digests using Enzyme A and Enzyme B. 
 
 
 
 
 
 
 
 
The digests were incubated overnight at 37
o
C in a thermal cycler. Enzymes were inactivated 
at 65
o
C for 20 minutes following digestion.  
 
The RT² SYBR
®
 Green/ROX
®
 qPCR master mix contained all of the optimized reagents and 
buffers needed for SYBR
®
 Green based real-time PCR. The master mix includes buffer, 
HotStart DNA Taq polymerase, nucleotides and ROX
®
 (used as a reference dye to normalise 
the qPCR instruments, Stratagene Mx3000p). For each of the four DNA digests an individual 
  Mo Ms Md Msd 
Nuclease-free H2O  8.62 7.42 7.42 6.22 
5X Digestion Buffer 3.6 3.6 3.6 3.6 
enzyme A 0 1.2 0 1.2 
enzyme B 0 0 1.2 1.2 
BSA 0.18 0.18 0.18 0.18 
Genomic DNA 25ng/µl (1µg)   5.6 5.6 5.6 5.6 
Total 18 18 18 18 
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PCR cocktail was prepared and carefully added to the PCR array (see Table 3) and then 
placed in the Stratagene Mx3000p (see Table 4 for program setting). 
 
Table 3 
A. Setting up SYBR® Green based real-time PCR cocktails. 
 
 Mo Ms Md Msd 
H2O 75µl 75µl 75µl 75µl 
PCR Master Mix   82.5µl 82.5µl 82.5µl 82.5µl 
Mo Digest 7.5µl - - - 
Ms Digest - 7.5µl - - 
Md Digest - - 7.5µl - 
Msd Digest - - - 7.5µl 
Total 165µl 165µl 165µl 165µl 
 
B. Samples were mixed and 25µl was carefully added to the PCR array: 
 
Sample 1  
Sample 2  
Sample 3  
Sample 4  
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Table 4 
The qPCR reaction was run in a two-step program on the Stratagene Mx3000p.  
 
  Cycles Temperature Duration 
1 95
o
C 10 mins 
40 
97
o
C 15 secs 
72
o
C 1 min 
 
 
3.5.2.1.Obtaining Cycle Threshold Values (Ct)  
 
In real-time PCR a positive reaction is detected by accumulation of a fluorescent signal, the 
SYBR green dye binds to double stranded DNA and fluoresces. As more double stranded 
DNA amplicons are produced during the PCR reaction the intensity of the fluorescent 
emissions will increase. The cycle threshold (Ct) is defined as the number of cycles required 
for the fluorescent signal to cross the threshold (i.e. exceeds background level). Ct levels are 
inversely proportional to the amount of target nucleic acid in the sample (i.e. the lower the Ct 
level the greater the amount of target nucleic acid in the sample). 
 
After the cycling program was completed for the Methyl-Profiler PCR arrays, the Ct values 
were obtained. The baseline and threshold values were manually set. To define the baseline, 
the linear view of the amplification plots was used and only readings from cycle number 2 
through to the cycle just before the earliest visible amplification were selected. To define the 
threshold values, the log view of the amplification plots was used, and threshold values above 
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the background signal but within the lower third of the linear portion of the amplification 
curves were selected (see Figure 6). 
 
Finally, all Ct values were transferred to an Excel analysis template file supplied by 
SABiosciences. The template automatically performs the calculations from the raw Ct values 
to determine the gene promoter methylation status. The template normalises the digest Ct 
values to the mock digest Ct values and finally the percentage of the DNA that is 
hypermethylated is calculated.   
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Figure 6 
qPCR amplication plots. A. Linear View. B. Logarithmic View.    
A 
 
B 
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3.6. Cell Culture → 96-well format 
 
3.6.1.  SH-SY5Y Neuroblastoma Stock 
 
SH-SY5Y human neuroblastoma cells were purchased from ECACC and grown in DMEM/F-
12 1:1 supplemented with 10% FCS, 100U penicillin-streptomycin and 2mM L-glutamine, at 
37°C in 5% CO2, humidified atmosphere. Passage number did not exceed 20 and cells did not 
reach senescence. Cells were frozen (-80°C) in foetal calf serum containing 10% DMSO at a 
density of 5 million cells/ml.  
  
3.6.2. Setting Up Cultures From Frozen Cells  
 
Cells were washed in DMEM/F-12 1:1 (w/o glutamine) and suspended in culture medium 
(DMEM/F-12 1:1 supplemented with 10% FCS (PAA), 100U/ml penicillin-streptomycin 
(Invitrogen) and 2mM L-glutamine (Sigma Aldrich)) to achieve a cell density of 500,000 
cells/ml. Cells were plated into 25cm
2
 flasks, and allowed to settle for 48 hours at 37°C in 5% 
CO2, humidified atmosphere. After the cells had settled, the culture medium was replaced 
with the same culture medium supplemented with 10µM retinoic acid (Tocris). The cells were 
allowed to differentiate for 5 days, with new culture medium containing 10µM retinoic acid 
replaced each day. At day six, the culture medium was removed and replaced with 2ml of 
1mM EDTA in PBS. This was left on the cells for 10 minutes. Flasks were gently tapped to 
dislodge the cells, and the supernatant was transferred to DMEM/F-12 1:1 (w/o glutamine). 
Cells were washed and then suspended in culture medium supplemented in retinoic acid to 
achieve a cell density of 100,000 cells/ml. Cells were plated in 96-well flat bottom tissue 
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culture treated plates (Becton Dickinson) and 100µl cell suspension was dispensed into each 
well (10,000 cells/well). Cells were allowed to settle for 24 hours at 37°C in a humidified 
incubator containing 95% air and 5% CO2.  
 
3.6.3. Treatment Schedules 
 
On day 7 one batch of differentiated cells were collected and used as a control for propidium 
iodide, immunocytochemistry and LDH assay, see Table 5:   
Table 5 
Cell culture 8-day treatment schedule. 
 Treatment Collection 
Day 0 Set up in Flask - 
Day 1 Grow - 
Day 2 
10µM Retinoic Acid 
treatment 
- 
Day 3 
10µM Retinoic Acid 
treatment 
- 
Day 4 
10µM Retinoic Acid 
treatment 
- 
Day 5 
10µM Retinoic Acid 
treatment 
- 
Day 6 
Set up in 96-well plates - 
10µM Retinoic Acid 
treatment 
- 
Day 7 
Drug + ApoE Isoforms 
treatment  
Control - 0hr collection  
Day 8 - 
24hr collection 
Treated Plates 
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The rest of the cells were treated with either D-L-homocysteine (10, 20, 40, 80, 160 µM) or 
L-Cysteine (5, 10, 20, 40, 80 µM) (Sigma Aldrich) in the presence of 5µg/ml human 
recombinant ApoE isoforms (2, 3, or 4) (BioVision). Drugs were diluted in culture medium 
supplemented with retinoic acid. 100µl of homocysteine solution was added per well, (see 
Table 6 for plate layout). Cells were left overnight at 37°C in a humidified incubator 
containing 95% air and 5% CO2.  
Table 6 
96 Plate Layout 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
C
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E
) 
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D
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B 
C 
D 
E 
F 
G 
H 
 
 
Note - Identical cultures were also set up in 25cm
2
 flasks to obtain large enough cell numbers 
to allow RNA and DNA extraction for subsequent gene expression and methylation analysis. 
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3.6.4. Collection Of Cells  
 
Identical sets of culture plates were collected for different assays. From plates collected for 
immunocytochemistry the supernatant was gently aspirated and cells were fixed (in-situ) with 
100µl of Glyo-Fixx (Shandon-Thermo Scientific) for 2 hours followed by incubation with 
100µl of 85% ice-cold ethanol. (Note - The plates collected for cytometry were fixed with 
85% ice-cold ethanol only).  
 
From the plates collected for LDH (cell proliferation and survival assay) 50µl of supernatant 
was removed from each well and transferred to a clean 96-well plate (for the measurement of 
dead cells) and stored at -20
o
C until LDH Assay was performed.  
 
In the 25cm
2
 flasks at day 8, the culture medium was removed and replaced with 2ml of 1mM 
EDTA in PBS. This was left on the cells for 10 minutes. Flasks were gently tapped to 
dislodge the cells, and the supernatant was transferred to DMEM/F-12 1:1 (w/o glutamine). 
Cells were washed, supernatant removed, and pellet frozen at -80
o
C. RNA, DNA and Protein 
Extraction were performed as described on page 16. 
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3.6.5.  Immunocytochemistry  
 
3.6.5.1.Phospho-Tau (AT8) and Beta-Amyloid 
 
Ethanol was aspirated from the wells. 100µl of Blocking Solution (PBS, 0.1% triton X-100 
and 5% BSA) was added to each well. Plates were incubated at room temperature for 30 
minutes. Blocking solution was aspirated and 50µl of primary antibody was added; either 
mouse monoclonal amyloid-β (1:100, Dako) or mouse monoclonal PHF-Tau, AT8 (1:200, 
Innogenetics).  
 
For the negative controls, PBS with 0.1% triton X-100 was applied instead of the primary 
antibody. From this step onwards, the control plates were treated exactly as the treated 
cultures. Plates were incubated overnight at 4
o
C. 
 
Cells were washed twice with 200µl of PBS with 0.1% triton X-100.  Primary antibodies were 
detected by incubating overnight at 4
o
C with 100µl of anti-mouse IgG - FITC (1:200, 
Abcam). Cells were washed twice with 200µl of PBS with 0.1% triton X-100, and 100µl of 
propidium iodide staining solution (100µg/ml RNase A, 10µg/ml Propidium iodide 0.1% 
Triton-X-100) was added to each well (see Table 7 for plate set up). Plates were incubated at 
37 °C for 20 minutes and protected from the light. 
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Table 7 
96 well plate set up for immunocytochemistry: 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Zero day control, labelled 
with Beta Amyloid or AT8, 
and stain with PI 
Negative control for 
immuno-cytochemistry 
B 
C 
D 
E 
F 
G 
H 
 
 
3.6.5.2.Measurement and Acumen Explorer
®
 Analysis 
 
The Acumen Explorer
®
 Microplate Cytometer (TTP LabTech Ltd) was used to scan the 96-
well cell cultures in situ. Propidium iodide was used to measure DNA content and to establish 
the cell cycle phase of individual cells. Furthermore, using antibodies to label tau and beta 
amyloid we could carry out secondary analysis to measure changes in protein expression and 
the expression of protein in different cell cycle phases. We used green-fluorescent for protein- 
and red-fluorescent for cell cycle analysis. Cytometry data was transferred to our standard 
mathematical model, which allowed calculation of the length of the different phases of the 
cell cycle and protein content.   
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3.6.6.  Cyto Tox 96® Non-Radioactive Cytotoxicity Assay 
 
The number of dead cell in the cultures was determined using a commercially available kit 
(CytoTox 96 non-radioactive Cytotoxicity Assay, Promega) that quantitatively measures 
lactate dehydrogenase (LDH) release upon cell lysis. The method relies on the conversion of a 
tetrazolium salt by LDH into a red formazan product. SY-SH5Y cells diluted in culture 
medium where used to generate a calibration curve.  
 
Cell culture supernatant samples (see 3.6.4) were thawed and kept at 4
oC before use. 50μl of 
ice-cold reconstituted substrate buffer was added to each well. Plates were incubated at room 
temperature and protected from light. Reaction was stopped with 50μl of stop solution and 
absorbance read at 490nm. Cell numbers are directly proportional to the absorbance values 
which represent LDH activity. The number of cells that have died in the cultures were derived 
from the standard curve containing set cell numbers of the same type. The Hcy-induced 
change in cell death was calculated as the ratio of dead cells in Hcy treated cultures and 
controls and expressed as a percentage.     
 
Chapter 2 Methods 
 
40 
 
3.7. Statistics  
 
Statistical analysis was carried out using the MedCalc
®
 software package. Kruskall Wallis 
analysis was used if data was not normally distribution. Two factor analysis of variance 
(ANOVA) and multi-factor analysis of variance (MANOVA) was used to analyse the 
interactions between Hcy levels and ApoE genotype. Multiple regression analysis was used to 
analyse Hcy levels as a continuous variable. Furthermore, to analyse variables independent of 
disease severity z-scores were generated for each variable. This gave a measure of the 
standard deviation from the group mean. In some instances we have dichotomised continuous 
variables into binary categories (such as ‘smaller than’ or ‘greater than’ the observed group 
mean). The binary transformation allows for the use of logistic regression to test for the 
possible predictors of an outcome
194
. If the p-values were < 0.05 then this was regarded as 
statistically significant. Note - due to the relatively low patient number no age and sex 
correction were possible.   
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4. RESULTS 
 
4.1. The Effect of Homocysteine and ApoE on the Development of AD 
(HYPOTHESIS 1 and HYPOTHESIS 2)  
 
We analyzed the effect of the ApoE genotype and plasma as well as brain Hcy levels on 
markers of disease severity and evolution in a cohort of Alzheimer’s disease patients and 
controls. The number of samples analysed was not based on power calculations, but was 
determined by tissue availability.   
 
4.1.1. The Effect of Homocysteine on Disease Severity  
 
We defined disease severity based on Braak Staging
62
. Using one-way analysis of variance 
(ANOVA) we found that the levels of plasma Hcy (as measured at most three years before 
death) was not different in the different patient groups (Figure 7). Additionally the frequency 
of elevated plasma Hcy levels (above the accepted normal 15 µM) was not different in these 
groups (see Figure 8 and Table 8 for Chi-square test). However, we found that patients 
suffered from additional vascular pathology, elevated plasma Hcy levels were associated with 
more severe Alzheimer-type pathology (Figure 9).  
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Figure 7  
A one-way analysis of variance (ANOVA) was conducted with the levels of plasma Hcy as 
the dependent variable and the severity of disease as the independent variable. Plasma Hcy 
levels (absolute values, µM) on y-axis and disease severity (E = entorhinal, L = limbic, and N 
= neocortical) on x-axis.  Error bars represent standard error of the mean.  Top of bars 
represent mean. (p = 0.850, df = 2). 
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Figure 8 
Effect of disease severity on the distribution of patients with different plasma Hcy levels. A 
Chi-square test was conducted with the severity of disease as the dependent variable and the 
plasma Hcy levels as the independent variable. Plasma Hcy levels (<15 and >15µM - absolute 
values) and disease severity (E = entorhinal, L = limbic, and N = neocortical).  (p = 0.1128, df 
= 2).  
 
Table 8 
Frequency of elevated plasma Hcy in individuals in different stages of AD. Disease severity - 
pre-clinical (entorhinal), mild (limbic) and severe (neocortical). 
 Severity of Disease  
 
Pre-clinical AD Mild AD Severe AD 
Relative 
Frequency 
<15µM 7 - (8.3%) 15 - (17.9%) 24 - (28.6%) 54.8% 
>15µM 8 - (9.5%) 5 - (5.9%) 25 - (29.8%) 45.2% 
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Figure 9 
Effect of disease severity on the distribution of plasma Hcy levels in patients with 
additional vascular disease. A Chi-square test was conducted with the severity of disease 
as the dependent variable and the plasma Hcy levels as the independent variable. 
Plasma Hcy levels (<15 and >15µM - absolute values) and disease severity (E = 
entorhinal, L = limbic, and N = neocortical).  (p = 0.1779, df = 2). 
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We have also found that disease free survival (age of onset in demented patients and age at 
death in the non-demented elderly) was significantly higher in patients with elevated plasma 
Hcy levels (p=0.04), see Figure 10.  
 
Using the age of onset and the age of death we calculated the duration of the disease in 
demented patients. Z-scores were calculated for each patient group (to avoid the effect of 
disease severity on disease duration). We found that the patients with elevated levels of 
plasma Hcy had a significantly shorter disease duration (p=0.024) than patients with normal 
plasma Hcy level, see Figure 11. 
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Figure 10 
The effect of plasma Hcy on disease free survival. An ANOVA was conducted with the 
disease free survival as the dependent variable and the levels of plasma Hcy as the 
independent variable. Age of disease free survival (on y-axis) and plasma Hcy levels 
dichotomised to smaller than or greater than 15µM (on x-axis).   (p = 0.04, df = 1). Error bars 
represent standard error of the mean.  Top of bars represent mean.  
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Figure 11 
The effect of plasma Hcy on disease duration. An ANOVA was conducted with the disease 
duration as the dependent variable and the levels of plasma Hcy as the independent variable. 
z-score values for disease duration (on y-axis) and plasma Hcy levels dichotomised to smaller 
than or greater than the mean of the group (on x-axis).  (p = 0.024, df = 1). Error bars 
represent standard error of the mean.  Top of bars represent mean. 
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Similar analysis was performed to study the effects of brain Hcy measurements. We found a 
weak trend showing that the levels of brain Hcy decreased with increasing severity of AD 
(Figure 12 and Table 9). No association was found between brain Hcy levels and age of onset 
or disease duration (data not shown). 
 
Table 9 
Frequency of elevated brain Hcy in different stages of AD. Disease severity - pre-clinical 
(entorhinal), mild (limbic) and severe (neocortical). 
 
 Severity of Disease  
 
Pre-clinical AD Mild AD Severe AD 
Relative 
Frequency 
Brain Hcy < mean 7 - 13.5% 5 - 9.62% 22 - 42.3% 65.4% 
Brain Hcy > mean 6  - 11.5% 4 - 7.69% 8 - 15.3% 34.6% 
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Figure 12 
Analysis of brain Hcy levels and disease severity. A Kruskal-Wallis test was conducted with 
the levels of Brain Hcy as the dependent variable and the disease severity as the independent 
variable. Brain Hcy levels (absolute values normalized to protein concentration, µM/g of 
protein) on y-axis and disease severity (E = entorhinal, L = limbic, and N = neocortical) on x-
axis. (p = 0.1316, df = 2). Error bars represent standard error of the mean.  Top of bars 
represent mean. 
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To analyse the relationship between ApoE genotype and disease severity we dichotomised the 
ApoE genotypes into two groups: ApoE ɛ4 non-carriers (allele = 0) and carriers (either one or 
two ɛ4 alleles = 1). We found significantly higher percentage of ApoEɛ4 carriers among 
neocortical stage patients (see Figure 13 and Table 10).  
 
Using z-score values for age of onset and disease duration, we found that the age of disease 
onset was earlier and the duration of disease much longer in ApoE4 carriers compared to non-
carriers, although these associations were not statistically significant (see Figure 14 and 
Figure 15).  
 
 
Table 10 
Frequency of ApoE4 genotype in different stages of AD. Disease severity - pre-clinical 
(entorhinal), mild (limbic) and severe (neocortical). (chi-squared = p < 0.0001). 
 
 Severity of Disease  
 
Pre-clinical AD Mild AD Severe AD 
Relative 
Frequency 
ApoE ε4 non-
carriers 
14 - (15.7%) 14 - (15.7%) 15 - (16.9%) 48.3% 
ApoE ε4 carriers 2 - (2.2%) 7 - (7.9%) 37 - (41.6%) 51.7% 
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Figure 13 
Analysis of ApoE4 genotype and disease severity. A Chi-square test was conducted with the 
severity of disease as the dependent variable and the ApoE4 genotype as the independent 
variable. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1). Disease severity (E = entorhinal, L = limbic, and N = neocortical) on x-axis.   (p 
< 0.0001, df = 2). 
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Figure 14 
Analysis of ApoE4 genotype and age of onset. A Kruskal-Wallis test was conducted with the 
age of last normal as the dependent variable and the ApoE4 genotype as the independent 
variable. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1) on x-axis. Age of onset (dichotomised to smaller than or greater than the mean of 
the group) on y-axis. (p = 0.1397, df = 1). Error bars represent standard error of the mean.  
Top of bars represent mean. 
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Figure 15 
Analysis of ApoE4 genotype and disease duration. A Kruskal-Wallis test was conducted with 
the disease duration as the dependent variable and the ApoE4 genotype as the independent 
variable. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1) on x-axis. Disease duration (dichotomised to smaller than or greater than the mean 
of the group) on y-axis. (p = 0.1830, df = 1). Error bars represent standard error of the mean.  
Top of bars represent mean. 
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We carried out two way analysis of variance to assess whether the effect of plasma Hcy on 
disease duration (see Figure 10) was dependent on the ApoE genotype. The analysis indicates 
that the effect of Hcy, in terms of accelerating the disease process is mainly present in patients 
with the ApoE4 allele but not in patients who do not carry the ApoE4 (see Figure 16).    
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Figure 16 
The combined effect of plasma Hcy and ApoEɛ4 genotype on disease duration. An ANOVA 
was conducted with the disease duration as the dependent variable and the levels of Hcy and 
the ApoE4 genotype as the independent variables. z-score values for disease duration on y-
axis and plasma Hcy levels (dichotomised to smaller than or greater than the mean of the 
group) on x-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either 
one or two alleles = 1). Error bars represent standard error of the mean.  Top of bars represent 
mean. 
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4.1.2. The Effect of Homocysteine on Cognitive Function 
 
 
We have relied on CAMCOG scores taken from the last cognitive assessment before death 
(not more than 6 months prior to death) to analyse cognitive function. Plasma Hcy levels had 
no effect on the final cognitive status of the patients (data not shown). Brain Hcy levels did 
not influence the CAMCOG score either (data not shown). 
 
As the percentage of ApoE4 carriers is significantly higher in neocortical stage patients than 
entorhinal or limbic stage patients, (Figure 13) the analysis of ApoE ε4 effect on cognitive 
function was carried out using CAMCOG scores normalised to disease severity. The ApoE 
genotype did not influence the CAMCOG score or loss of CAMCOG score per disease month 
(data not shown). Finally, two-way analysis of variance was used to analyse the combined 
effect of Hcy and ApoE4 genotype on cognitive function. Including the ApoE genotype in the 
analysis did not alter the lack of effect Hcy has on cognitive function (see Figure 17).  
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Figure 17 
The combined effect of plasma Hcy and ApoEɛ4 genotype on CAMCOG score. An ANOVA 
was conducted with CAMCOG scores as the dependent variable and the levels of Hcy and the 
ApoE4 genotype as the independent variables. z-score values for CAMCOG score on y-axis 
and plasma Hcy levels (dichotomised to smaller than or greater than the mean of the group) 
on x-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1). Error bars represent standard error of the mean.  Top of bars represent mean. 
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4.1.3. The Effect of Homocysteine on Pathology 
 
We analysed the effect of Hcy on the accumulation of AD-type pathology and oxidative 
stress. AD-related pathology (AT8-positive phospho-tau, DC11 positive NFTs and beta 
amyloid), synaptic remodelling, synaptic density and oxidative stress markers were analysed 
separately for the three different lobes (i.e. lateral temporal, frontal and occipital lobe).  
 
Tau phosphorylation and NFT formation 
 
We investigated the relationship between disease severity and tau-related pathology using two 
antibodies: AT8 and DC11. AT8 recognises hyperphosphorylated tau (p-tau) prior to tangle 
formation, while DC11 detects hyperphosphorylated tau present in tangles. The amount of p-
tau significantly increases with AD progression (see Figure 18).  
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Figure 18 
Analysis of p-tau in the lateral temporal lobe and disease severity. An ANOVA was 
conducted with AT8 expression as the dependent variable and the disease severity as the 
independent variable. AT8 expression (absolute values) on y-axis. Disease severity (E = 
entorhinal, L = limbic, and N = neocortical) on x-axis. (p < 0.001, df = 2). Error bars 
represent standard error of the mean.  Top of bars represent mean.   
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Depending on the distribution of data, parametric ANOVA test or non-parametric Kruskal-
Wallis test were used to analyse the effect of elevated plasma Hcy on the accumulation of 
AD-type pathology. We found that patients with elevated plasma Hcy levels had higher AT8 
and DC11 expressed in all brain regions. The same is seen with brain Hcy levels. Statistically 
significant differences were only found with DC11 expression in the lateral temporal lobe in 
patients with elevated plasma Hcy (p = 0.0256) and elevated brain Hcy levels (p = 0.0404), 
see Figure 19.  
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Figure 19 
A - Plasma Homocysteine Levels 
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Figure 19 
B - Brain Homocysteine Levels  
Effect of Hcy levels on the accumulation of tangle pathology in the lateral temporal lobe. An 
ANOVA was conducted with DC11 expression as the dependent variable and the levels of 
plasma/brain Hcy as the independent variable. z-score values for DC11 expression on y-axis. 
Plasma/brain Hcy levels (dichotomised to smaller than or greater than the mean of the group) 
on x-axis. p = 0.0256, df = 1 and p = 0.0404, df = 1 respectively. Error bars represent standard 
error of the mean.  Top of bars represent mean. 
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The ApoE genotype did not influence the expression of DC11 in the lateral temporal lobe (see 
Figure 20).  
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Figure 20 
Analysis of ApoE4 genotype and tangle pathology in the lateral temporal lobe. A Kruskal-
Wallis test was conducted with DC11 expression as the dependent variable and the ApoE4 
genotype as the independent variable.z-score values  for DC11 expression on y-axis. ApoEɛ4 
non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 1) on x-
axis. (p = 0.569, df = 1). Error bars represent standard error of the mean.  Top of bars 
represent mean.  
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Two-way analysis of variance was used to analyse the combined effect of Hcy level and 
ApoE4 genotype on DC11 expression in the lateral temporal lobe. We found that this 
relationship became non-significant in ApoE ε4 carriers in the lateral temporal lobe (see 
Figure 21). This interaction between ApoE4 and Hcy levels was even more pronounced, and 
statistically significant (p=0.033, df = 1) if we taken into account the brain Hcy (see Figure 
22).  
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Figure 21 
Two way analysis of variance. The combined effect of plasma Hcy and ApoEɛ4 genotype on 
tangle pathology in the lateral temporal lobe. An ANOVA was conducted with the DC11 
expression as the dependent variable and the plasma Hcy levels and the ApoE4 genotype as 
the independent variable. z-score values for DC11 expression on y-axis and plasma Hcy 
levels (dichotomised to smaller than or greater than the mean of the group, µM) on x-axis. 
Chapter 3 Results 
 
63 
ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 
1). Error bars represent standard error of the mean.  Top of bars represent mean. 
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Figure 22 
Two way analysis of variance. The combined effect of brain Hcy and ApoEɛ4 genotype on 
tangle pathology in the lateral temporal lobe. An ANOVA was conducted with the DC11 
expression as the dependent variable and the brain Hcy levels and the ApoE4 genotype as the 
independent variable. z-score values for DC11 expression on y-axis  and brain Hcy levels 
(dichotomised to smaller than or greater than the mean of the group, µM) on x-axis. ApoEɛ4 
non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 1). Error 
bars represent standard error of the mean.  Top of bars represent mean. 
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Beta Amyloid  
One of the hallmarks of AD is extracellular insoluble amyloid plaques composed of beta 
amyloid.  Kruskal-Wallis test was used to investigate if beta amyloid expression related to 
disease severity. The expression of beta amyloid in the frontal and occipital lobe significantly 
increased with AD progression (see Figure 23).  
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Figure 23 
Relationship between disease severity and beta amyloid accumulation. A Kruskal-Wallis test 
was conducted with the beta amyloid expression as the dependent variable and the disease 
severity as the independent variable. z-score values for beta amyloid expression in the frontal 
lobe on the y-axis. Disease severity (E = entorhinal, L = limbic, and N = neocortical) on x-
axis. (p = 0.0101, df = 2). Error bars represent standard error of the mean.  Top of bars 
represent mean. 
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Using z-scores we analysed the effect of Hcy on beta-amyloid expression independently of 
disease severity. Kruskal-Wallis analysis showed that beta amyloid expression in the temporal 
lobe was significantly increased in patients with elevated brain Hcy levels (see Figure 24). A 
similar trend is seen with plasma Hcy levels (Figure 25), although results failed to reach 
statistical significance.  
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Figure 24 
Effect of brain Hcy levels on the accumulation of beta amyloid in the lateral temporal lobe. A 
Kruskal-Wallis test was conducted with the beta amyloid expression as the dependent variable 
and the brain Hcy levels as the independent variable. z-score values for beta amyloid 
expression on y-axis. z-score values for brain Hcy levels (dichotomised to smaller than or 
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greater than the mean of the group, µM/protein) on x-axis. (p = 0.0499, df = 1). Error bars 
represent standard error of the mean.  Top of bars represent mean. 
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Figure 25 
Effect of plasma Hcy levels on the accumulation of beta amyloid in the lateral temporal lobe. 
A Kruskal-Wallis test was conducted with the beta amyloid expression as the dependent 
variable and plasma Hcy levels as the independent variable. ᵶ-score values for beta amyloid 
expression on y-axis. z-score values for plasma Hcy levels (dichotomised to smaller than or 
greater than the mean of the group, µM/protein) on x-axis. (p = 0.1639, df = 1). Error bars 
represent standard error of the mean.  Top of bars represent mean. 
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Beta amyloid expression in the lateral temporal lobe was significantly higher in ApoEɛ4 
carriers (see Figure 26) than non-carriers. Two-way analysis of variance was used to analyse 
the combined effect of Hcy levels and ApoE4 genotype on beta amyloid expression in the 
lateral temporal lobe. ApoEɛ4 non-carriers with high plasma Hcy levels were found to have 
significantly higher levels of beta amyloid in the temporal lobe, while in ApoE4 carriers 
plasma Hcy levels had no significant effect. Similar interactions was seen when brain Hcy 
levels were used to analyse the data (see  
Figure 27 and Figure 28).   
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Figure 26 
Analysis of ApoE4 genotype and beta amyloid expression in the lateral temporal lobe. A 
Kruskal-Wallis test was conducted with the beta amyloid expression as the dependent variable 
and the ApoE genotype as the independent variable.  ᵶ-score values for beta amyloid 
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expression on y-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either 
one or two alleles = 1) on x-axis.( p = 0.0415, df = 1). Error bars represent standard error of 
the mean.  Top of bars represent mean. 
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Figure 27 
Two way analysis of variance. The combined effect of plasma Hcy and ApoEɛ4 genotype on 
beta amyloid expression in the lateral temporal lobe. An ANOVA was conducted with beta 
amyloid expression as the dependent variable and the levels of plasma Hcy and the ApoE4 
genotype as the independent variables. ᵶ-score values for beta amyloid expression on y-axis 
and plasma Hcy levels (dichotomised to smaller than or greater than the mean of the group, 
µM) on x-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one 
or two alleles = 1). Error bars represent standard error of the mean.  Top of bars represent 
mean. 
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Figure 28 
Two way analysis of variance. The combined effect of brain Hcy and ApoEɛ4 genotype on 
beta amyloid expression in the lateral temporal lobe. An ANOVA was conducted with beta 
amyloid expression as the dependent variable and the levels of brain Hcy and the ApoE4 
genotype as the independent variables. ᵶ-score values for beta amyloid expression on y-axis 
and brain Hcy levels (dichotomised to smaller than or greater than the mean of the group) on 
x-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1). Error bars represent standard error of the mean.  Top of bars represent mean. 
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4.1.4. The Effect of Homocysteine on Oxidative Stress  
 
4-hydroxynonenal (4-HN) and 8-hydroxyguanosine (8-HG) were used as markers of oxidative 
stress.  ANOVA was used to investigate the relationship between disease severity and the 
expression of these oxidative stress markers. We found no significant relationship between 
oxidative stress and disease progression (data not shown).   
 
Logistic regression analysis was used to investigate the relationship between oxidative stress 
markers and Hcy levels. 4-HN expression in the lateral temporal lobe positively correlated 
with brain Hcy levels (close to significance p = 0.0608, see Table 11). The ApoEɛ4 genotype 
did not influence this relationship. Furthermore, 4-HN expression in the frontal lobe 
positively correlated with brain Hcy levels (see Table 12). In the frontal lobe of ApoEɛ4 
carriers the Hcy-induced 4-HN levels were significantly lower than in those without the 
ApoE4 allele (Table 12). This interaction is also reflected in the fact that high brain Hcy 
levels are associated with increased 4-HN expression primarily in ApoE4 carriers, but not in 
patients who do not have this isoform (see Figure 29).  8-HG expression in the frontal lobes 
also showed a positive correlation to brain Hcy levels; however the ApoEɛ4 genotype did not 
influence this relationship (see Table 13, p= 0.0022). 
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Table 11 
Relationship of 4-HN expression in the lateral temporal lobe with Hcy levels and ApoEɛ4 
genotype. A logistic regression analysis was conducted using z-score values dichotomised to 
smaller than or greater than the mean of the group. With 4-HN expression in the lateral 
temporal lobe as the dependent variable and the levels of Hcy and the ApoE4 genotype as the 
independent variables.ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers 
(either one or two alleles = 1). p=0.0608. 
 
   
   
 
 
Table 12 
Relationship of 4-HN expression in the frontal lobe with Hcy levels and ApoEɛ4 genotype. A 
logistic regression analysis was conducted using z-score values dichotomised to smaller than 
or greater than the mean of the group. With 4-HN expression in the frontal lobe as the 
dependent variable and the levels of Hcy and the ApoE4 genotype as the independent 
variables. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1). p=0.0057. 
 4-HN Frontal Lobe 
 Variable Coefficient Std. Error P 
Brain Hcy levels 0.7437 0.3897 0.0564 
ApoE4 -1.6105 0.6493 0.0131 
   
 4-HN Lateral Temporal Lobe 
 Variable Coefficient Std. Error P 
Brain Hcy levels 0.7066 0.4198 0.0924 
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Figure 29 
The relationship of brain Hcy, ApoEɛ4 genotype and 4-HN expression in the frontal lobe. A 
ANOVA was conducted using 4-HN expression in the frontal lobe as the dependent variable 
and the levels of Hcy and the ApoE4 genotype as the independent variables.z-score values for 
4-HN expression in the frontal lobe on y-axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) 
and ApoEɛ4 carriers (either one or two alleles = 1) on x-axis. z-score values for brain Hcy 
levels (dichotomised to smaller than or greater than the mean of the group, µM). Error bars 
represent standard error of the mean.  Top of bars represent mean. 
 
Chapter 3 Results 
 
73 
 
Table 13 
Relationship of 8-HG expression in the frontal lobe with Hcy levels and ApoEɛ4 genotype. A 
logistic regression analysis was conducted using z-score values dichotomised to smaller than 
or greater than the mean of the group. With 8-HG expression in the frontal lobe as the 
dependent variable and the levels of Hcy and the ApoE4 genotype as the independent 
variables. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1). p=0.0022. 
 
 
   
 
 8-HG Frontal Lobe 
   Variable Coefficient Std. Error P 
Brain Hcy Levels 1.3484 0.5649 0.0170 
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4.1.5. Relationship Between Brain Homocysteine and Plasma Homocysteine 
Levels 
 
 
Levels of Hcy in the CSF have been reported to be 5-30% of that of plasma. We used brain 
tissue to measure levels of Hcy; this allowed us to analyse if there was any relationship 
between the levels of Hcy in the brain and the levels measured in plasma within the last 4 
years prior to death. The Hcy levels were normalized for disease severity and transformed to 
z-scores values (see Methods). This allowed us to study the relationship between brain Hcy 
and plasma Hcy levels, independent of disease severity. We found no association between the 
two variables (see Figure 30).  
 
Hcy is an intermediary in sulfur-amino acid metabolism and is a link between methionine and 
folate. Taking this into consideration we decided to look at the relationship between Hcy and 
methionine level. Firstly, we analysed the relationship between brain Hcy and brain 
methionine levels. We found no association between the two variables (see Figure 31) and the 
Hcy/methionine ratio in the brain was mainly determined by the brain Hcy levels (R
2
 value = 
86.8%, p<0.0001; see Figure 32).  
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Figure 30  
Correlation analysis of brain Hcy levels and plasma Hcy levels (z-scores), R
2
 value = 21.9%, 
p = 0.1266.     
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Figure 31 
Correlation analysis of Hcy and methionine levels in the brain (z-scores), R
2
 value = 0.8%, p 
= 0.518.     
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Figure 32 
Correlation analysis of brain Hcy and brain Hcy/methionine ratio (ᵶ-scores), R2 value = 
86.8%, p<0.0001.  
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4.1.6. Global DNA Methylation 
 
 
Any change in the Hcy/methionine ratio could potentially result in changes to the methylation 
capacity. In consideration of this, we decided to analyse global DNA methylation.  Firstly, we 
investigated the relationship between global DNA methylation and disease severity. We found 
a trend showing that the % of global methylated DNA was reduced in patients with 
neocortical stage AD compared to that of patients in an entorhinal or limbic stage of AD (see 
Figure 33).      
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Figure 33 
A Kruskal-wallis test was conducted using the % of global DNA methylation as the dependent 
variable and the disease severity as the independent variables. % of global DNA methylation 
(absolute values) on y-axis and disease severity (E = entorhinal, L = limbic, and N = 
neocortical) on x-axis. (p = 0.0901, df = 2). Error bars represent standard error of the mean.  
Top of bars represent mean. 
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Next using the z-score values we decided to look at the relationship between global DNA 
methylation and Hcy levels (both in brain and plasma). There was no association between 
global DNA methylation and Hcy levels. Furthermore, analysis using methionine levels and 
the Hcy/methionine ratio yielded no significant relationship with global DNA methylation 
(data not shown). Additionally we found that the presence or absence of the ApoEɛ4 allele did 
not alter this pattern (see Table 14). 
 
 
ApoEɛ4 carriers were found to have a slightly reduced global DNA methylation compared to 
non- carriers (see Figure 34), although the result failed to reach statistical significance. 
However this can be interpreted as a larger number of neocortical stage patients being 
ApoEɛ4 carriers.  
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Figure 34 
Analysis of ApoE4 genotype and % of global DNA methylation. A Kruskal-wallis test was 
conducted using the % of global DNA methylation as the dependent variable and the ApoE4 
genotype as the independent variables. % of global DNA methylation (absolute values) on y-
axis. ApoEɛ4 non-carriers (no ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two 
alleles = 1) on x-axis. (p = 0.150, df = 1). Error bars represent standard error of the mean.  
Top of bars represent mean. 
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Table 14 
Multiple regression analysis with % global methylation as the dependent variable and Hcy 
measurements (z-score values) and ApoEɛ4 genotype as independent variables. p = 0.054.  
 
 % Global Methylation Status 
Independent variables Coefficient Std. Error P 
ApoE4 -0.2289 0.1134  0.0540 
   
Variables not included in the model 
Plasma Hcy levels 
Brain Hcy levels 
Brain Hcy/methionine ratio 
Brain methionine levels 
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4.1.7. The Effect of Homocysteine on the Methylation of Cyclin Dependent 
Kinase Inhibitor Genes  
 
Following our analysis of global DNA methylation, we decided to investigate the relationship 
between Hcy and the methylation status of CDKI genes.  
 
Firstly, we investigated the relationship between CDKI methylation (absolute values) and 
disease severity to see if the methylation of CDKI genes changed at different stages of AD. 
Using Kruskal-Wallis analysis we found no relationship between the severity of disease and 
the methylation of CDKI genes (data not shown).  
 
Using z-score values, the effect of Hcy and ApoEɛ4 genotype on CDKI methylation was 
analysed by multiple regression analysis. We found, with a backward regression model, a 
number of independent variables (brain Hcy levels and Hcy/methionine ratio) that contributed 
to the p16
INK4a
 methylation status. ApoEɛ4 genotype had no effect on p16 INK4a methylation 
(see Table 15). The promoter methylation of the other CDKI genes was not affected by Hcy 
levels in the brain (data not shown).   
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Table 15 
Multiple regression analysis with p16
INK4a
 methylation as the dependent variable and Hcy 
measurements (z-score values) and ApoEɛ4 genotype as independent variables. p = 0.053.  
 
  p16
INK4a
 promoter methylation 
 Independent variables Coefficient Std. Error P 
Brain Hcy Levels 1.0204 0.4071  0.0227 
Brain Hcy/Methionine ratio -1.0056 0.3911  0.0198 
   
Variables not included in the model 
Plasma Hcy Levels 
Brain Methionine Levels 
ApoE4 
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4.1.8. The Effect of Homocysteine on Protein Expression of Cyclin Dependent 
Kinase Inhibitors  
 
 
After analysing CDKI methylation status, we next wanted to investigate if the levels of Hcy 
influenced the expression of CDKI at the protein level.  
 
Firstly we decided to see if the levels of CDKI were altered at different stages of AD. We 
found trends showing that levels of CDKI (p16
INK4a
, p21
cip1
, p27
kip1
 and p57
kip2
) were at their 
highest at later stages of AD. Using Kruskal-Wallis analysis, statistically significant 
differences were only found with p21
cip1
 expression in the lateral temporal and occipital lobe 
(see Figure 35 and Figure 36).   
 
Using z-score values, we found that the methylation status of the CDKI genes did not 
correlate with the expression of the CDKI protein (data not shown).  
 
Finally we analysed the relationship between Hcy levels and the expression of CDKIs. Plasma 
Hcy levels did not influence CDKI expression. Elevated levels of brain Hcy were 
significantly associated with decreased expression of p16
INK4a
 in the occipital lobe (Figure 
37). Including ApoEɛ4 genotype in this analysis showed that the effect of the Hcy was 
stronger in patients who did not carry the ApoEɛ4 allele (Figure 38). 
 
We also found that patients with elevated brain Hcy levels had significantly higher expression 
of p27 and p57 in the occipital lobe (Figure 39 and Figure 41 respectively).  This Hcy-
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associated increase in the expression of p27/p57 is only present in patients who are ApoE ε4 
carriers (Figure 40 and Figure 42 respectively).  
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Figure 35 
p21
cip1
 expression in the lateral temporal lobe of individuals in different stages of AD. A 
Kruskal-wallis test was conducted using p21 expression as the dependent variable and the 
disease severity as the independent variable. Disease severity on the x-axis (E = entorinal, L = 
Limbic, N = Neocortical); p21 expression in the lateral temporal lobe on the y-axis. (p = 
0.0086, df = 2).   Error bars represent standard error of the mean.  Top of bars represent mean. 
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Figure 36  
p21
cip1
 expression in the occipital lobe of individuals in different stages of AD. A Kruskal-
wallis test was conducted using the p21 expression as the dependent variable and the disease 
severity as the independent variable. Disease severity on the x-axis (E = entorinal, L = 
Limbic, N = Neocortical); p21 expression in the occipital lobe on the y-axis. (p = 0.0362, df = 
2).   Error bars represent standard error of the mean.  Top of bars represent mean. 
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Figure 37 
Effect of brain Hcy levels on p16
INK4a
 expression in the occipital lobe. A Kruskal-wallis test 
was conducted using p16 expression as the dependent variable and brain Hcy levels as the 
independent variables. z-score values for p16
INK4a
 expression in the occipital lobe on y-axis. 
z-score values for brain Hcy levels (dichotomised to smaller than or greater than the mean of 
the group) on x-axis. (p = 0.042, df = 1). Error bars represent standard error of the mean. Top 
of bars represent mean. 
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Figure 38 
The relationship of brain Hcy, ApoEɛ4 genotype and p16INK4aexpression in the occipital lobe. 
An ANOVA was conducted using p16 expression as the dependent variable and the brain Hcy 
levels and the ApoE4 genotype as the independent variables. z-score values for p16
INK4a
 
expression in the occipital lobe on y-axis. z-score values for brain Hcy levels (dichotomised to 
smaller than or greater than the mean of the group, µM) on x-axis. ApoEɛ4 non-carriers (no 
ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 1). (p = 0.139, df = 1). 
Error bars represent standard error of the mean. Top of bars represent mean. 
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Figure 39 
Effect of brain Hcy levels on p27
kip1
 expression in the occipital lobe. A Kruskal-wallis test 
was conducted using p27 expression as the dependent variable and the brain Hcy levels as the 
independent variable. z-score values for p27
Kip1
 expression in the occipital lobe on y-axis. z-
score values for brain Hcy levels (dichotomised to smaller than or greater than the mean of 
the group) on x-axis. Kruskal wallis test. (p = 0.018, df = 1). Error bars represent standard 
error of the mean.  Top of bars represent mean. 
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Figure 40 
The relationship of brain Hcy, ApoEɛ4 genotype and p27Kip1 expression in the occipital lobe. 
An ANOVA was conducted using p27 expression as the dependent variable and the brain Hcy 
levels and the ApoE4 genotype as the independent variables. z-score values for p27
Kip1
 
expression in the occipital lobe on y-axis. z-score values for brain Hcy levels (dichotomised to 
smaller than or greater than the mean of the group) on x-axis. ApoEɛ4 non-carriers (no 
ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 1). (p = 0.040, df = 1). 
Error bars represent standard error of the mean.  Top of bars represent mean. 
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Figure 41 
Effect of brain Hcy levels on p57
Kip2
 expression in the occipital lobe. A Kruskal wallis test 
was conducted using p57 expression as the dependent variable and the brain Hcy levels as the 
independent variable. z-score values for p57
Kip2
 expression in the occipital lobe on y-axis. z-
score values for brain Hcy levels (dichotomised to smaller than or greater than the mean of 
the group) on x-axis. (p = 0.005, df = 1). Error bars represent standard error of the mean.  Top 
of bars represent mean. 
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Figure 42 
The relationship of brain Hcy, ApoEɛ4 genotype and p57Kip2 expression in the occipital lobe. 
An ANOVA was conducted using p57 expression as the dependent variable and the brain Hcy 
levels and the ApoE4 genotype as the independent variables. z-score values for p57
Kip2
 
expression in the occipital lobe on y-axis. z-score values for brain Hcy levels (dichotomised to 
smaller than or greater than the mean of the group) on x-axis. ApoEɛ4 non-carriers (no 
ApoEɛ4 allele = 0) and ApoEɛ4 carriers (either one or two alleles = 1). (p = 0.019, df = 1). 
Error bars represent standard error of the mean.  Top of bars represent mean. 
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4.2. IN VITRO STUDY 
(HYPOTHESIS 3) 
To study the effects of Hcy on neurones and its possible interaction with ApoE we set up in 
vitro experiments using the SH-SY5Y human neuroblastoma cell line. This cell line 
differentiates into cells with morphological characteristics of neurones such as neurite 
outgrowth, and expresses neurone-specific markers (e.g. β-tubulin III). Additionally this cell 
line expresses the AD-related proteins tau and amyloid precursor protein (APP). Using this 
model we could investigate directly the effect of Hcy and ApoE on cell survival, AD-related 
pathology and cell cycle kinetics.  
 
The SH-SY5Y human neuroblastoma cultures were pre-differentiated for 5 days with 10µM 
retinoic acid. This was followed by a 24 hour treatment with D-L homocysteine with and 
without the human recombinant ApoE isoforms. Cell death was quantified by LDH assay. 
ACUMEN cytometry was used to analyse the cell cycle kinetics. The LDH assay in 
combination with ACUMEN cytometry allowed calculation of population doubling times and 
the length of the individual phases of the cell cycle. AD related expression of phospho-tau 
(AT8) and beta amyloid were measured in different cell populations using the ACUMEN 
cytometer. 
 
Note: A separate neuroblastoma culture was set up and treated with L-Cysteine (data not 
shown). The results of the analysis of the L-Cysteine cultures were different the results of the 
analysis of the D-L homocysteine treated cultures. This confirms that the results seen in the 
D-L homocysteine treated cultures were due only to Hcy, and not because Hcy was converted 
to cysteine via the transsulfuration pathway.  
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4.2.1. The Effect of Homocysteine and ApoE on Cell Proliferation, Cell Death 
and Cell Cycle Kinetics.  
 
 
We have used cell cytometry (following propidium iodide staining) to assess cell numbers, 
apoptotic cells and cell cycle kinetics. Using the cytometry data, coupled with the LDH assay 
results (measuring necrotic cell death), our standard mathematical model allowed the 
calculation of the length of the different phases of the cell cycle and the population doubling 
times.   
 
After 24 hours of Hcy treatment at doses >5uM, we found a significant increase (p<0.05) in 
the cell numbers, with a slight drop in cell numbers at the highest dose (Figure 43a). Necrotic 
cell death was reduced at lower doses and then returned to control level at high doses, i.e. 
above 40µM (see Figure 43a grey). The population doubling times significantly decreased 
with Hcy treatment (Figure 43b).   
 
Key   
Homocysteine only -  Black  
Homocysteine & ApoE2 - Green  
Homocysteine & ApoE3 - BLUE  
Homocysteine & ApoE4 – Red 
 
(Note - Key for Figure 43 to Figure 54) 
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 A 
 
 B 
Figure 43 
Homocysteine Only. The effect of Hcy (µM) on cell proliferation. A – Live cells (black) and 
dead cells (grey). B – Population doubling times (hours).   
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In the presence of recombinant ApoE2 isoform, the cell numbers significantly decrease with 
Hcy concentration >20µM, (Figure 44a green). The reduction of live cell numbers is parallel 
to the increase of dead cell numbers (Figure 44b grey). Significant decrease in the population 
doubling times is only notable at Hcy concentrations >20µM (Figure 44b).  
  A 
  B 
Figure 44 
The effect of Hcy (µM) in the presence of ApoE2 on cell proliferation. A – Live cells (green) 
and dead cells (grey). B – Population doubling times (hours).   
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With ApoE3 isoform supplementation, there was no significant change in the live cell 
numbers with Hcy treatment (Figure 45a blue). However dead cell number was found to 
significantly decrease in Hcy treated cultures (Figure 45a grey). A slight increase in the 
population doubling times at low doses is associated with a significant reduction in cell death 
(Figure 45a & b). At high doses, the Hcy-induced inhibition of cell proliferation disappears 
without a significant increase in cell death.  
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 A 
  B 
Figure 45 
Homocysteine and ApoE3 
The effect of Hcy (µM) in the presence of ApoE3 on cell proliferation. A – Live cells (blue) 
and dead cells (grey). B – Population doubling times (hours).   
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Finally, in the presence of the ApoE4 isoform, live cell numbers do not change significantly 
with Hcy treatment in the cultures (Figure 46a red). However, increasing concentrations of 
Hcy is associated with increasing cell death (Figure 46a grey), leading to a gradually 
decreasing population doubling time (Figure 46b).   
   A 
  B 
Figure 46 
Homocysteine and ApoE4 
The effect of Hcy (µM) in the presence of ApoE4 on cell proliferation. A – Live cells (red) 
and dead cells (grey). B – Population doubling times (hours).   
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The addition of ApoE to the cultures reduces populations doubling time, significantly 
reversing some of the differentiating effect of retinoic acid (Figure 47a). The baseline 
proliferation time in the presence of ApoE is almost identical for the three isoforms.   
 
However, the addition of Hcy to the cultures treated with ApoEelicits a different isoforms 
dependent effect (Figure 47b). In the presence of ApoE2, Hcy levels up to 20µM have no 
significant effect on cell proliferation, whereas higher concentrations of Hcy elicit a 
significant and dose dependent increase in the speed of proliferation (decrease in population 
doubling times). With ApoE3 treatment, Hcy at low doses (below 20µM) increases baseline 
population doubling time (slows proliferation). This effect disappears at higher doses. =In 
ApoE4 treated cultures, Hcy leads to a steady dose dependent decrease in population doubling 
times that appears to level out with treatment above 40µM (Figure 47b).  
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 B 
Figure 47 
ApoE Isoforms 
A - The effect of the ApoE isoforms on cell proliferation. B – The effect of the ApoE 
isoforms and Hcy (µM) on cell proliferation. ApoE2 (green), ApoE3 (blue), ApoE4 (red). 
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The changes of the population doubling times in Hcy treated cultures are associated with 
alterations of the cell cycle kinetics in an isoforms dependent manner.  
 
In the ApoE2 treated cultures, higher doses of Hcy (i.e. above 40µM) leads to an 
accumulation of cells in the G2 phase of the cell cycle, at the expense of the G1 fraction 
(Figure 48a). This trend in the ApoE3 cultures is only seen at the highest concentration of 
Hcy (Figure 48b). While this effect disappears entirely in the presence of ApoE4 (Figure 48c).   
 
A 
Figure 48 
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Figure 48 
The effect of the ApoE isoforms and Hcy (µM) on the % of G1 and G2 cells. A – ApoE2. B -  
ApoE3 and C - ApoE4. 
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4.2.2. The Effect of Homocysteine and ApoE on AD-Related Pathology 
 
4.2.2.1. Phospho-tau production 
 
In the neuroblastoma cell line the baseline p-tau levels (AT8 positive) are significantly higher 
in G2 phase cells that in G1 cells (Figure 48a). The addition of the fraction of p-tau containing 
cells is different in the two sub-populations is also significantly different ((Figure 48b).). 
Baseline levels of p-tau are slightly different in cultures treated with different ApoE isoforms 
(Figure 48c).  
 
The effects of Hcy are significantly different in cultures treated with the different ApoE 
isoforms. Hcy alone has very little effect on overall p-tau expression. At very high doses the 
p-tau content of the G2 cells increases, but there is no alteration in the number of p-tau 
containing G2 cells (Figure 49). In the presence of ApoE2, high dose Hcy treatment reduces 
the cellular p-tau expression compared to that of cells treated with no or low dose Hcy (Figure 
50a). This reduction in p-tau level is due to a response to high Hcy in both the G1 and G2 cell 
populations (Figure 50b). In the G1 population, there is a reduction in the number of p-tau 
positive cells combined with a reduction of p-tau content of the positive cells (Figure 50c and 
d). While in the G2 population, the reduction in p-tau expression of the whole population is 
only associated with a reduction in p-tau expression of the positive cells, and not associated 
with a reduction in the number of cells that express the protein (Figure 50c and d). 
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Figure 48 
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 C  
Figure 48 
A - The p-tau content in G1 and G2 cells. B - The % of p-tau positive G1 and G2 cells. B -
The effect of the ApoE isoforms on p-tau expression. ApoE2 (green), ApoE3 (blue), ApoE4 
(red). 
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 A 
 
 B 
Figure 49  
Homocysteine Only - The effect of Hcy (µM) on p-tau accumulation. A – AT8 expression per 
cell. B – AT8 expression in G1 and G2 cells. C – Percentage of AT8 positive G1 and G2 
cells. 
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C 
Figure 49  
Homocysteine Only - The effect of Hcy (µM) on p-tau accumulation. A – AT8 expression per 
cell. B – AT8 expression in G1 and G2 cells. C – Percentage of AT8 positive G1 and G2 
cells.  
Chapter 3 Results 
 
110 
 
 
 
 A 
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Figure 50 
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C 
 D 
Figure 50 
The effect of Hcy (µM) in the presence of ApoE2 on p-tau accumulation. A – AT8 expression 
per cell. B – AT8 expression in G1 and G2 cells. C – Percentage of AT8 positive G1 and G2 
cells. D - Percentage of AT8 in G1 and G2 positive cells.  
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In ApoE3 treated cultures, Hcy increases AT8 expression in a dose dependent manner (Figure 
51a). This increase is more significant in the G2 cell population with no effect on the G1 
population (Figure 51b). The significant change in the G2 population is due entirely to the 
increase of the p-tau content of these cells as there is no change in the number of positive G2 
cells (Figure 51c & d). 
 
ApoE4 with Hcy does not affect p-tau levels significantly in the population as a whole (Figure 
52a). The positive cell numbers and p-tau content of both G1 and G2 cell populations seem 
unaffected by Hcy (Figure 52c-d). 
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Figure 51   
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D 
Figure 51 
The effect of Hcy (µM) in the presence of ApoE3 on p-tau accumulation. A – AT8 expression 
per cell. B – AT8 expression in G1 and G2 cells. C – Percentage of AT8 positive G1 and G2 
cells. D - Percentage of AT8 in G1 and G2 positive cells. 
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Figure 52 
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D 
 
Figure 52 
The effect of Hcy (µM) in the presence of ApoE4 on p-tau accumulation. A – AT8 expression 
per cell. B – AT8 expression in G1 and G2 cells. C – Percentage of AT8 positive G1 and G2 
cells. D - Percentage of AT8 in G1 and G2 positive cells.   
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When comparing the Hcy induced changes in AT8 expression, in the cultures treated with the 
different ApoE isoforms, we found that the levels of p-tau increased in the ApoE3 treated 
cultures. In the presence of ApoE2, there was a decrease from baseline with treatment above 
10µM of Hcy. The only change seen in the presence of ApoE4, was at 10µM of Hcy 
treatment, where there was a decrease from baseline (see Figure 53).  
 
 
Figure 53 
The effect of the ApoE isoforms and Hcy (µM) on AT8 expression. ApoE2 (green), ApoE3 
(blue), ApoE4 (red). 
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4.2.2.2. Beta Amyloid- Positive Cells 
 
 
Similar to the p-tau cell cytometry results, the beta amyloid content of the G2 cells is always 
significantly higher than that of G1 cells.  Furthermore, a significantly larger fraction of the 
G2 cell population contains beta amyloid than that of the G1 population (see Figure 54a).   
 
Addition of the ApoE isoforms to the cultures significantly alters the beta amyloid expression 
per cell compared to that of the control cultures: there is higher beta amyloid expression per 
cell in the presence of ApoE2 compared to ApoE3 and ApoE4 (Figure 54b). 
 
The beta amyloid levels show minor fluctuations in the cultures treated with the different 
ApoE isoforms, but there is no obvious dose dependent change induced by Hcy in the 
different cultures (Figure 54c). However, due to the difference in the baseline beta amyloid 
level in the three cultures, the absolute levels of beta amyloid are significantly higher in the 
presence of ApoE2 and ApoE4 compared to ApoE3 (Figure 54d).  
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Figure 54 
The effect of the ApoE isoforms and Hcy (µM) on beta amyloid expression. A - Beta amyloid 
content in G1 and G2 cells. B - Beta amyloid expression in the presence of ApoE isoforms. C 
- Percentage of beta amyloid in the whole population with increase Hcy concentration (µM). 
D -. Beta amyloid expression (absolute values) in the whole population. ApoE2 (green), 
ApoE3 (blue), ApoE4 (red). 
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4.2.3. The Effect of Homocysteine and ApoE on the Methylation of Cell Cycle 
Regulatory Genes.   
 
 
Using differentiated SH-SY5Y human neuroblastomas, we could directly investigate the 
effect Hcy and ApoE isoforms have on the methylation status of CDKI genes.  
 
p16
INK4a
 gene promoter analysis revealed that, in the presence of ApoE3, low doses of Hcy (5 
and 20µM) lead to a slight increase in methylation, while the high dose lead to a decrease in 
methylation of the promoter (see Figure 55a). In the presence of ApoE4, increasing 
concentrations of Hcy increase the methylation of p16
INK4a
. In the ApoE4 treated cultures, the 
methylation status of the promoter is significantly lower at baseline, and significantly higher 
from 20µM Hcy concentration than in the ApoE3 treated cultures.   
 
p15
INK4b
 promoter methylation status did not change with increasing Hcy concentration in the 
presence of ApoE3 (see Figure 55b). With ApoE4 supplementation, 80µM of Hcy was found 
to increase p15
INK4b
 methylation to 0.45%. No significant difference was seen between 5 and 
20µM Hcy treatment in the presence of ApoE4 (0.01 & 0.02% respectively).  
 
For p21
cip1
, p27
kip1 
and p57
kip2
 promoter methylation we calculated an overall average for the 
methylation status of the three promoter regions. In the presence of ApoE3, we see an 
interesting bell-shaped dose curve in response to increasing Hcy concentrations. While, in the 
Chapter 3 Results 
 
122 
presence of ApoE4, the methylation of these genes is upregulated by even the lowest dose of 
Hcy concentration, see Figure 56.  
 
 A 
 B 
Figure 55 
The effect of Hcy (µM) on the methylation status of the INK genes. A. p16
INK4a 
promoter 
gene. B. p15
INK4b
 promoter gene.  
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Figure 56 
The effect of Hcy (µM) on the methylation status of the cip/kip genes.  
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5. DISCUSSION 
 
In 1990, Reyland et al were the first to publish findings associating elevated plasma Hcy 
levels with AD
63
. In 1993, Strittmatter and co-workers found a relationship between late-onset 
AD and ApoE4 genotype. Elevated plasma Hcy levels and ApoE4 genotype are now 
considered to be risk factors for both AD and cerebrovascular disease. Since the early 1990s, 
a number of studies have investigated the possible pathogenic mechanisms by which these 
factors may influence the development of AD. We hypothesise that there could be a possible 
interaction between the two risk factors and their pathogenic effect may depend on the two 
risk factors being present together.  
 
5.1. Frequency of Elevated Homocysteine levels in Alzheimer’s Disease  
 
Normal levels of plasma Hcy range from 5 to 15µmol/L. Plasma levels above 15µmol/L are 
regarded as hyperhomocysteinemia. Hyperhomocysteinemia can vary in severity: levels 
between 15 and 30µmol/L are regarded as moderate; the range from 30 to 100µmol/L is 
regarded as intermediate; and levels >100µmol/L is regarded as severe. From our cohort, last 
plasma Hcy level measurements taken before death were available to study. Plasma Hcy 
levels were dichotomised to below 15µM and above 15µM; where below 15µM was 
considered as normal and above 15µM was considered as elevated. There was no difference 
in the frequency of elevated plasma Hcy in individuals in different stages of AD.  
 
The prevalence of hyperhomocysteinemia in the elderly population is ~40%
64;65
. In a large 
group of hospitalised elderly patients investigated, 63% of dementia patients were found to 
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have hyperhomocysteinemia. The lack of difference seen in our cohort is very difficult to 
interpret due to the low patient numbers compared to other studies.         
 
With regards to the brain Hcy levels, there are very few studies that have examined levels of 
Hcy in brain tissue. In our cohort, severe AD patients appeared to be more likely to have 
higher brain Hcy levels; however this was not statistically significant and in light of the small 
patient numbers is difficult to interpret. 
 
 
5.2. Plasma Homocysteine and Brain Homocysteine 
 
It has been shown that serum Hcy, stored at -20
o
C, is stable for 20 years
73
.Considering this, 
we decided to measure Hcy levels in brain tissue that had been stored at -80
o
C. This would 
allow us to analyse the direct effect of Hcy on the central nervous system; and gives a 
measure of Hcy at the time of death. 
 
In a study with cystathionine beta-synthase deficient (CBS-/-) mice, that were fed on a 
methionine rich diet, it was postulated that elevated plasma Hcy levels could disrupt the 
integrity of the blood brain barrier and expose the brain to toxic levels of Hcy
74
. Furthermore, 
in a study involving patients with hyperhomocysteinaemia, that were given vitamin B 
supplements, the supplementation was  found to improve blood brain barrier function
75
. It is 
interesting to note that the ApoE4 genotype has also been linked to compromising the 
integrity of the blood brain barrier
76
. 
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In the brain, levels of Hcy are found to be 5-30% of that of plasma
32;33
. Active transport via 
carrier proteins occurs at the blood brain barrier. However, a literature search has shown no 
specific carrier for Hcy. Furthermore, inducing folate deficiency in the brain via 
intraventricular administration of methotrexate (anti-folate drug) was found to increase CSF 
Hcy levels. This may suggest that the Hcy that is found in the brain may originate from the 
brain itself. Levels of Hcy in the CSF and plasma have been analysed in amyotrophic lateral 
sclerosis (ALS) patients: this study showed no relationship between CSF Hcy and plasma 
Hcy
77
. This is further supported by our data where no association was found between plasma 
Hcy and brain Hcy levels (see Figure 30).     
   
We analysed the relationship between brain Hcy levels and methionine levels and found no 
association (see Figure 31). However, elevation of brain Hcy is associated with an increase in 
the Hcy/methionine ratio (see Figure 32), demonstrating that methionine levels remain stable 
even when Hcy levels are elevated. Studies have shown that folate and vitamin B12 
deficiencies result in elevated levels of Hcy and low levels of methionine and SAM. The 
authors suggest that the lack of folate and vitamin B12 inhibit conversion of Hcy to 
methionine
78
. This is not supported by our findings that indicate that brain Hcy and 
methionine levels change independently of one another. 
 
5.3. The Effect of Homocysteine on the Onset of Disease and  disease Duration 
 
Numerous studies have associated increases in plasma Hcy levels with age
4
. However, there 
are very few studies investigating the influence of plasma Hcy levels on age of onset of AD. 
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Guidi et al found that patients with late-onset AD (>65 years) had significantly elevated levels 
of plasma Hcy compared to early-onset patients (<65 years), (20.1 ± 0.9µM versus 14.3 ± 
1.2µM respectively)
79
. The lack of association of elevated plasma Hcy with early-onset AD 
suggest that elevated plasma Hcy may not play a role in this form of the disease. The authors 
explain that the difference in plasma Hcy levels between early and late-onset age-matched AD 
patients was a result of vascular disease, which is prevalent in late-onset patients
80
. This is one 
of the reasons why patients with vascular disease were excluded from our study and only pure 
AD patients were considered. 
 
To ascertain if plasma Hcy is a possible contributor to the pathogenesis of AD, studies have 
examined levels of Hcy over the duration of the disease. Clarke et al showed that plasma Hcy 
measurements remained stable over a 3 year disease period
34
. Furthermore, in a 2004 study, it 
was shown that patients with elevated plasma Hcy levels at initial stages of the disease did not 
exhibit further increases in plasma Hcy levels several years into the disease period (initial and 
final plasma Hcy recorded - 13.0 ± 2.8µM and 13.2 ± 2.8µM respectively)
81
. These studies 
call into question whether elevated plasma Hcy is a consequence of AD. The lack of 
association of plasma Hcy levels with disease duration in these studies suggest that elevated 
plasma Hcy levels occurs early on in AD.  
 
In our study we looked at the age of disease onset in relation to plasma Hcy levels. Patients 
with elevated plasma Hcy levels had a significantly higher age of onset (p=0.015), see Figure 
10. On first observation, this could suggest that elevated plasma Hcy levels delay AD onset. 
On closer analysis, we found that patients with elevated plasma Hcy levels that had a higher 
age of onset also had a significantly shorter disease duration (p=0.024), see Figure 11. Whilst 
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their symptoms may have presented at a later age, they had a more rapid decline, causing 
death in a shorter period of time. Nilsson et al’s 2004 study found no relationship between 
plasma Hcy and disease duration
81
. However, another 2004 study by McCaddon et al
82
 
showed that patients with a longer disease duration had lower levels of plasma Hcy. This 
finding is replicated by our results.  
 
A second aim of the study was to see if the effects of Hcy are dependent on the ApoE 
genotype. We found no indication that the ApoE genotype would have an influence on the 
effect of Hcy on the age of onset or disease duration. When looking at the effect of the ApoE 
genotype alone, we found that ApoEɛ4 carriers had an earlier age of onset with a longer 
duration of AD (see Figure 14 and Figure 15): an opposite trend to that of patients with 
elevated plasma Hcy. These findings replicate the results from the Gomez-Isla et al study that 
demonstrated a younger age of onset of AD in patients that were ApoEɛ4 carriers. They also 
showed that ApoEɛ4 carriers had a longer disease duration.  ApoE4 carriers did not have a 
faster rate of disease progression than non-carriers of ApoE4. As there was no association of 
ApoEɛ4 genotype with the rate of progression of the disease, the authors concluded that the 
longer disease duration in ApoEɛ4 carriers was due to the earlier age of onset of the disease83. 
From our study, as we do not have a measure of rate of progression, we cannot conclude 
whether the longer disease duration seen in ApoE ε4 carriers is only due to an earlier age of 
onset.    
 
To summarise, we found that elevated plasma Hcy levels were associated with a later age of 
onset of AD and a shorter disease duration. This may suggest that elevated plasma Hcy levels 
accelerate the rate of progression of the disease. In the literature there are inconsistencies 
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between studies examining relationships between disease duration and plasma Hcy levels. 
This can be explained by the difficulty in defining the ‘disease duration’. Although onset of 
disease is defined as the time when the symptoms of AD first present, obtaining an exact 
measure is complicated. Firstly, symptoms of AD could go unnoticed for a long period of 
time by both the patient and relatives. Secondly, the amount of pathology associated with the 
appearance of symptoms may differ significantly between patients.   
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5.4. The Effect of Homocysteine on Disease Severity 
     
Higher plasma or brain Hcy levels were not associated with more severe AD in our pure AD 
patients. This finding has been previously observed in past studies
84-87
. Nilsson et al looked at 
the severity of dementia using the Katz ADL-Index and Berger Scale to assess physical and 
social dependency respectively. They also classified severity of disease as mild, moderate and 
severe. The study found that plasma Hcy levels positively correlated with the severity of AD 
type dementia
81
. The majority of studies looking at AD severity and plasma Hcy levels 
support the notion that elevated plasma Hcy is associated with AD
34;64;85;88-94
. .  
 
We analysed patients with vascular disease in addition to AD, and found that a higher 
frequency of the patients had elevated plasma Hcy levels in the neocortical (severe) stage of 
AD compared to earlier stages, although the analysis failed to reach statistical significance 
(see Figure 9). A similar trend is also seen in other studies
81;95
. This does suggests that plasma 
Hcy levels may not be related to AD severity but could be a reflection of a relationship 
between vascular disease and plasma Hcy. Clarke et al found that both patients with 
histologically confirmed AD with vascular disease, and patients with vascular disease alone, 
had elevated plasma Hcy levels. But patients with histologically confirmed AD with no 
evidence of macroscopic vascular disease present also showed elevated levels of plasma Hcy. 
This suggests that elevated plasma Hcy levels are not a result of concomitant vascular disease 
in AD patients
34
. This highlights the need for us to exclude patients with vascular disease 
from our cohort, as a relationship between plasma Hcy and vascular disease could potentially 
mask the association between Hcy and AD.    
 
The lack of relationship between elevated plasma Hcy and AD that we see in our cohort was 
also seen by Nilsson and co-workers. They initially did not find a difference in plasma Hcy 
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levels between control and AD patients without vascular disease.  However, when they 
corrected plasma Hcy levels for plasma creatinine concentration, AD patients without 
vascular disease had significantly higher levels of plasma Hcy compared to control patients. 
Elevated Hcy in AD could be a consequence of renal dysfunction or vitamin deficiencies
96;97
. 
Plasma creatinine concentrations were used to normalise plasma Hcy levels as creatinine 
concentration is thought to relate to renal function and muscle mass
81
. One limitation of our 
study is that we do not have plasma creatinine levels. The lack of association between plasma 
Hcy and AD severity in our cohort could be partly due to the fact that no adjustment were 
made for levels of plasma creatinine.    
 
5.5. The Effect of Homocysteine on Cognitive Performance 
 
From my review of the literature I have been able to find only nine publications to date that 
do not show a relationship existing between elevated plasma Hcy levels and cognitive 
performance
84;85;87;98-102
. A 2000 study published by Ravaglia et al examined 54 healthy 
elderly subjects and found no association between plasma Hcy levels and  cognitive 
performance
102
. However, 4 years later Ravaglia and co-workers published findings from a 
larger healthy elderly cohort and found that elevated plasma Hcy was associated with poorer 
cognitive performance
103
. This suggests that a larger cohort is needed to reveal a relationship 
between plasma Hcy and cognition.   
 
Contrary to the above, there are a large number of cross-sectional studies that report an 
association between elevated plasma Hcy and cognitive decline
100;104-107
. It is difficult with 
these types of studies to ascertain that the elevated plasma Hcy is a cause of poor cognition. 
Prospective or longitudinal studies allow observation of cognitive performance over time and 
allow more accurate correlations between plasma Hcy levels and cognition to be made.  A 
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study by Garcia et al, followed a large cohort of subjects (n = 180) with normal cognitive 
performance at baseline. The study showed that at follow-up subjects with elevated plasma 
Hcy levels had significantly lower cognitive scores compared to their baseline values. Whilst 
cognitive scores remained at baseline in subjects with decreased plasma Hcy levels at follow-
up 
108-110
.  
 
Opposite to expectations set by the literature, we found that elevated plasma Hcy levels in life 
was associated with higher CAMCOG scores (close to significance) just prior to death. The 
lack of association between plasma Hcy levels and cognitive performance in our cohort could 
be due to us only using cross-sectional analysis on a relatively small number of patients. Also, 
using single measurements of plasma Hcy, as we have done in this study, have been shown to 
underestimate the relationship between Hcy and cognition by 15%
111;112
. Additionally, it 
important to note that many of our patients had severe dementia (very low cognitive scores) 
that may have been present for several years and this plateau effect may obscure the 
relationship between Hcy levels and dementia severity. However, there may be an alternative 
explanation. As patients with elevated plasma Hcy levels did not show a more rapid cognitive 
decline but were found to have a shorter disease duration, it is possible to envisage that 
elevated plasma Hcy levels may be associated with the premature death of the patient 
independently of their cognitive decline.         
   
There are a number of studies that have looked at the effect of plasma Hcy on cognitive 
functioning, but very few studies have investigated the combined effect of ApoE genotype 
and plasma Hcy on cognition. There are inconsistencies in the few studies that have examined 
the relationship between plasma Hcy, cognitive function and ApoEɛ4 genotype, Dufouil and 
co-workers conducted a longitudinal study, where plasma Hcy levels and cognition function 
were monitored in a healthy elderly cohort over a period of 4 years. Using baseline plasma 
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Hcy levels, and cognitive decline assessed by loss of MMSE scores, they found a significant 
association between elevated plasma Hcy levels and cognitive decline. Furthermore, Dufouil 
et al analysed the possible interaction of plasma Hcy and ApoEɛ4 genotype. They found that 
ApoE genotype did not modify the effect that plasma Hcy had on cognition
109
. Two years 
later, Schafer et al published findings from a study also involving a large group of healthy 
elderly subjects, and found that elevated plasma Hcy were associated with a worse 
neurobehavioral test score. Furthermore, contradictory to the 2003 Dufouil study, Schafer and 
co-workers found that ApoE genotype modified the effect of plasma Hcy levels. Subjects that 
were homozygous for the ApoEɛ4 allele (ɛ4ɛ4) had a significantly worse neurobehavioral test 
score compared to ApoEɛ4 non-carriers113. Finally in 2008, Elias et al provided further 
support to the Schafer et al study. They found that in subjects who were ApoEɛ4 non-carrier, 
plasma Hcy did not have an effect on cognitive performance. Whilst subjects carrying either 
one or two ApoEɛ4 alleles were able to modify the effect that elevated plasma Hcy had on 
cognitive function: analysis showed significantly worse cognitive test scores compared to 
ApoEɛ4 non-carriers50. In our cohort, no relationship between cognitive function and plasma 
Hcy was seen. This was also true when the ApoE genotype was taken into account.  
Furthermore, the ApoEɛ4 genotype alone did not influence cognitive performance, see Figure 
17. It is possible that our results just reflect the shortcomings of a cross sectional postmortem 
study (as discussed above) or it may be that the relationship between cognitive functioning 
and Hcy levels seen in the healthy population disappear in Alzheimer’s disease where 
cognitive functioning is affected mainly by the presence of pathology.  
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5.6. The Effect of Homocysteine on Pathology 
 
5.6.1. OPTIMA Cohort 
 
The two pathological hallmarks of AD are neurofibrillary tangles and neutric plaques. The 
accumulation of pathology varies between different brain regions and is related to the severity 
of AD
114
. The accumulation of pathology with disease progression in our cohort was 
consistent with previous studies
62
.    
 
The neurofibrillary tangles are composed of hyperphorylated tau. Tau plays an important 
function in maintaining the stability of microtubules. Therefore, tau has a fundamental role in 
maintaining neuronal structure and neuronal activity. The function of tau is regulated by the 
degree of phosphorylation: with hyperphosphorylation inhibiting microtubule binding and 
microtubule assembly. In AD brains, abnormally hyperphosphorylated tau accumulates to 
form of pair helical filaments (PHF), the major component of tangles
115-119
. In the current 
study we used AT8 to label hyperphosphorylated tau (p-tau) in its native state at Ser202 and 
Thr205. The AT8 antibody recognizes hyperphosphorylated tau prior to tangle formation. We 
also used another tau antibody (clone DC11), which recognises a tangle specific tau. The 
accumulating tau pathology relates to disease severity, see Figure 18. Using z-score values we 
were able to prevent the disease severity from masking the effect of Hcy and ApoE4 genotype 
on tau pathology.  
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We found that elevated levels of Hcy (whether in plasma or the brain) were associated with 
greater accumulation of p-tau and PHF-tau, and this association was independent of AD 
severity, see Figure 19.  
 
There are a number of studies that report a relationship between tangle pathology and ApoEɛ4 
genotype
19;120-122
. When analysing ApoEɛ4 genotype and its relationship to tau pathology, we 
found no relationship, see Figure 20. Contrary to studies that support a link between tau 
pathology and ApoEɛ4 genotype, there are a number of studies like ours that fail to find an 
association between tau pathology and ApoEɛ4 genotype70;106;123-126. There is a lack of studies 
looking at the combined effect of Hcy and ApoE genotype on tau pathology. We found that 
the association between elevated Hcy levels and more severe tau pathology in our cohort was 
mainly true in patients who did not carry the Apoε4 allele. In Apoε4 carriers the Hcy effect on 
tau pathology disappeared.  
 
Neuritic plaques composed of beta amyloid are another hallmark of AD. Beta amyloid is 
generated from the cleavage of the amyloid precursor protein (APP). Studies have associated 
APP gene mutations to early onset AD.  
 
In our cohort we see that with increasing disease severity there is an increase in the 
accumulation of beta amyloid in the frontal and occipital lobe (see Figure 23), regions of the 
brain that are affected later in the disease process. We found that patients with elevated Hcy 
levels (in plasma and the brain) had significantly higher levels of beta amyloid in the lateral 
temporal lobe, irrespective of disease severity (see Figure 24 and Figure 25). The lateral 
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temporal lobe was a region of the brain where beta amyloid accumulation might have reached 
a ceiling and was not associated with the disease severity.  
 
 Few studies have examined the relationship between plasma Hcy levels and beta amyloid 
expression in AD brain tissue. A number of studies have examined levels of plasma beta 
amyloid in relation to plasma Hcy, and demonstrated a strong correlation between the two 
variables
127-129
. One study has shown that, although levels of beta amyloid and Hcy in plasma 
are related, treatments such as vitamin B12 supplementation that lower plasma Hcy levels do 
not have an equivalent effect on beta amyloid levels. This suggests that once the pathological 
process has started it may be difficult to reverse it, or that the levels of beta amyloid are 
regulated independently of plasma Hcy
129
.  
 
Since both elevated Hcy levels and the ApoE ε4 status has a significant effect on amyloid 
accumulation, we analysed the combined effect of the two risk factors on this variable (see 
Figure 27 and Figure 28). We see a trend showing that patients with low Hcy levels and no 
ApoE ε4 have the lowest beta-amyloid expression in the lateral temporal lobe, whereas ApoE 
ε4 carriers with elevated Hcy have the highest amyloid load in the brain. Luchsinger et al’s 
study examined the combined effect of ApoE and Hcy on beta amyloid expression. They 
showed that although plasma Hcy was related strongly to beta amyloid levels in plasma, the 
association was unaffected by the ApoE genotype
128
. Our study shows a possible interaction 
between Hcy and ApoE genotype: indicating that elevated Hcy levels affect ApoE ε4 carriers 
more significantly in terms of beta amyloid accumulation. 
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5.6.2. In Vitro study 
 
To study the interaction between Hcy and ApoE at the cellular level and their effect on AD-
related protein expression, in vitro experiments were carried out using the SH-SY5Y 
neuroblastoma cell line. The cells were treated with physiological concentrations of Hcy 
combined with one of the three ApoE isoforms, and p-tau and beta amyloid expression was 
investigated.      
 
We chose our experimental range of Hcy concentrations to include normal and the highest 
plasma Hcy recorded in the OPTIMA cohort (~60µmol/L). The concentration of the human 
recombinant ApoE used in the cultures was 5µg/ml to match the physiological CSF 
concentrations of ApoE
130
.  
 
Anti-p-tau antibody (clone AT8) was used to detect hyperphosphorylated tau (p-tau) in the 
cultured neuroblastomas, and p-tau content was measured using ACUMEN cytometry. 
Several studies have indicated that increased Hcy levels are found to increase tau 
phosphorylation in SH-SY5Y neuroblastoma cells and other neuronal cells lines
131;132
. In the 
current study, a clear relationship between Hcy and tau expression is not seen in the Hcy only 
treated cultures. It was only when we analysed the different cell populations separately 
(defined by the cell cycle phase) that a significant increase in p-tau content was seen. At high 
Hcy doses, p-tau content per cell significantly increased in the G2 population. As the increase 
is only seen in the G2 population it could suggest that the intracellular signalling pathways 
activated by Hcy may cause aberrant upregulation of kinase activity leading to 
hyperphosphorylation of tau. Studies have shown that Hcy can induce cell proliferation
133
,  
and that entry into the cell cycle has been associated with increased tau phosphorylation
134
. 
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From our results it is evident that Hcy alone contributes to the development of AD not merely 
by de-regulating the cell cycle, but also increasing the p-tau content of the G2 cells. It is also 
interesting that the trend in p-tau accumulation in G2 cells is parallel to changes in cell death 
seen in the cultures, see Figure 43a. Could it be possible that high p-tau content in G2 cells is 
contributing to cell death? It has been shown in a number of studies that tau 
hyperphosphorylation and the accumulation of tau pathology correlates to cell death, as high 
p-tau content in neurones disrupts intracellular trafficking, which is critical for cell 
functioning
135;136
.  
 
When analysing the combined effect of Hcy and ApoE on p-tau expression, we see an isoform 
dependent effect. The presence of ApoE4 is shown to reverse the p-tau accumulation in G2 
cells, which was induced by increasing Hcy concentration (see Figure 52). This is not what 
we expected as ApoE4 is considered a strong genetic risk factor of AD. In ApoE2 treated 
cultures, we see a decrease in p-tau expression with high dose Hcy treatment (>10µM) in both 
G1 and G2 cells (see Figure 50b). In the presence of ApoE2, increasing Hcy concentrations 
are also found to reduce the rate of cell proliferation (see Figure 44a and Figure 51a 
respectively). This suggests that the influence of Hcy treatment alone on cell proliferation and 
tau phosphorylation is reversed in the presence of ApoE2. In G1 cells, we see that p-tau cell 
content, and the number of p-tau containing cells, is reduced with increasing Hcy dose (see 
Figure 51b and c); whilst in G2 cells there is only a reduction in p-tau content with no change 
in the number of p-tau positive cells. This suggests that the protective effect of ApoE2 occurs 
earlier on in the cell cycle. The findings from our study are consistent with the results of 
genetic studies that  indicate that the ApoE ε2 allele is protective in AD137.  
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Finally, in the presence of ApoE3 increasing Hcy concentration was found to increase the p-
tau content in G2 cells (see Figure 53). When analysing the p-tau cell content in relation to the 
cell death data (see Figure 45a), we can see that there is no significant change in cell death 
even though p-tau expression has significantly increased. This suggests that, in the presence 
of ApoE3, the cell death response is prevented even when p-tau is upregulated. Based on 
previous studies, ApoE3 has been shown to be more protective against apoptosis than ApoE4. 
In one particular study, ApoE3 was found to protect against apoptosis in retinal ganglion cells 
deprived of trophic additives, whilst ApoE4 did not protect the cells. ApoE can activate anti-
apoptotic signalling pathways via low density lipoprotein receptors. One proposed mechanism 
is that binding to LRP receptors leads to increased phosphorylation and inactivation of 
glycogen synthase kinase-3β (a pro-apoptotic kinase). Inactivation of glycogen synthase 
kinase-3β inhibits apoptosis138 is associated with decreased tau phosphorylation139. The ApoE 
ε3 allele is considered a neutral genotype in AD when compared to ApoE ε2 and ε4. Based on 
the p-tau and cell death data from our in vitro study, we can say that ApoE3 may not be able 
to inhibit the accumulation of tau induced by Hcy treatment, but may protect against 
apoptosis, allowing cells to survive for longer, despite tau accumulation within the cell.   
 
From our results Hcy does not seem to have a profound effect on the expression of beta 
amyloid. Based on our cohort analysis we see that elevated Hcy in the brain was associated 
with beta amyloid accumulation in the lateral temporal lobe, therefore we would have 
predicted a relationship with dose-dependent increases in beta amyloid content in our cells. 
One study has shown that Hcy potentiates the neurotoxic effects of beta amyloid when 
differentiated neuroblastoma cells are co-treated with beta amyloid peptides and high levels of 
Hcy
140
. The study suggests that the effects of Hcy may come into play once there already is an 
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accumulation of beta amyloid, and that Hcy is not directly a cause of beta amyloid 
accumulation.    
 
Cultures treated with ApoE2 and ApoE4 showed higher beta-amyloid expression than the 
cultures left untreated or treated with ApoE3, see Figure 54b. The lack of effect of Hcy 
treatment on beta amyloid cell content was not altered by the presence of the ApoE isoforms 
(data not shown). Finally, G2 cells showed a significantly higher beta amyloid content than 
G1 cells, see Figure 54a. This suggests that the upregulation of kinase activity in G2 cells 
could be contributing to aberrant phosphorylation of APP leading to the accumulation of beta 
amyloid
141
. Hcy may induce a proliferative response that activates mitogenic signalling 
pathways, but this proliferative response does not induce beta amyloid accumulation.    
 
In a recent study, severe hyperhomocysteinemia was induced through diet in an AD mouse 
model. After a period of 7 months, no change in the beta amyloid expression was found 
compared to the control mice
142
.  Both this study and our in-vitro study suggest that high 
levels of Hcy do not induce amyloidogenesis. 
 
Chapter 4 Discussion 
 
141 
5.7. The Effect of Homocysteine on Oxidative Stress in Alzheimer’s Disease 
 
Multiple studies suggest that oxidative stress and free-radical damage are involved in the 
pathogenesis of AD
84;143-145
. Oxidative stress results from an increase in free-radical 
production or a reduction in antioxidants. The brain is especially vulnerable to oxidative stress 
because of its high oxygen consumption and high lipid content
146
. The exact cause for the 
shift in oxidative homeostasis in AD is still unclear. We hypothesized that elevated Hcy levels 
would induce oxidative stress in the brain.    
 
In the current study, to identify lipid peroxidation and DNA oxidation we used anti-4-
hydroxynonenal (4-HN) and anti-8-hydroxyguanosine (8-HG) respectively. We initially 
investigated the relationship between oxidative stress and disease severity, and compared our 
results to the results of other studies
140;147
. We found that oxidative stress in the brain did not 
increase with AD progression. When analysing 4-HN and 8-HG expression in relation to Hcy 
levels using logistic regression, we found that oxidative stress predicted the levels of Hcy in 
the brain. This was close to significance in the lateral temporal lobe, and statistically 
significant in the frontal lobe (a region of the brain that is affected later on in the disease 
process). Patients that have oxidative stress (increased 4-HN expression) in the frontal lobe 
tended to be patients who were ApoE ε4 carriers with elevated brain Hcy levels (p = 0.0057). 
No relationship between oxidative stress and plasma Hcy was seen in our cohort, suggesting 
that only high levels of Hcy in the brain make the neurones susceptible to oxidative stress.  
 
Few studies have examined the combined effect of Hcy and ApoE genotype on oxidative 
stress. In a 2006 in-vitro study, folate deficiency (inducing elevated Hcy) in ApoE-/- mice 
was found to increase oxidative stress. The effect of folate deficiency on oxidative 
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homeostasis was potentiated by ApoE deficiency
148
. It is well documented that 30% of Hcy is 
in its free form, with the vast majority of Hcy protein bound. Of the unbound free Hcy 1-4% 
is in its reduced form
149
. When levels of Hcy in plasma increase, the protein binding sites for 
Hcy become saturated, and therefore it can be envisaged that there would be more free 
circulating reduced forms of Hcy
52
. As Hcy can undergo auto-oxidisation this would lead to 
the generation of reactive oxygen species, and would explain the relationship between 
oxidative stress and Hcy. We have found that the effect of brain Hcy on oxidative stress is 
ApoE dependent. Hcy can form disulfide bonds with cysteine residues on lipoproteins. 
Structural differences between the ApoE variants would influence Hcy binding. Hcy may 
have a lower binding capacity for ApoE4 due to the lack of cysteine residues on ApoE4 
compared to ApoE2 and ApoE3. Therefore, ApoE ε4 carriers would have higher amounts of 
free circulating Hcy, thus exposing the brain tissue to harmful levels of Hcy. In theory ApoE2 
and E3 carriers would be able to compensate for elevated Hcy levels by having more 
lipoprotein bound Hcy, thus reducing oxidative stress. We hypothesized that elevated Hcy 
levels induce oxidative stress, and that this effect is ApoE isoform dependent.  Our results 
support this hypothesis.   
 
 
5.8. The Effect of Homocysteine on Global DNA in Alzheimer’s Disease 
 
DNA methylation plays an important role in gene regulation. Promotor region 
hypermethylation results in transcriptional silencing of genes, while hypomethylation allows 
transcription factor binding and gene upregulation. Aging has been associated with the loss of 
global DNA methylation. Considering that aging is the biggest risk factor for AD, could 
aberrant changes in DNA methylation play a role in the pathogenesis of AD? Diseases such as 
Chapter 4 Discussion 
 
143 
cancer and atherosclerosis have also been associated with global DNA hypomethylation and 
gene-specific hypermethylation
150-156
. This further supports the need for investigating DNA 
methylation in AD.    
 
The methyl groups needed for DNA methylation are derived from dietary methyl donors such 
as methionine. Methionine is converted to s-adenosylmethionine, and then s-
adenosylhomocysteine, allowing methyl donations. S-adenosylhomocysteine is then 
converted to Hcy which is then remethylated to methionine (see Figure 2). Changes to the 
homeostasis of the folate cycle may alter the supply of methyl groups and therefore impact the 
biochemical pathways needed for DNA methylation.  
 
Initially we investigated the relationship between disease severity and global DNA 
methylation in our cohort. We found a trend showing that global DNA methylation decreases 
with AD progression, see Figure 33. The loss of global DNA methylation would increase 
genome instability which has been related to the aging process. Furthermore, extensive 
genomic hypomethylation could account for the upregulation of genes associated with AD 
pathology, as has been suggested in a number of papers
157-162
. In one paper looking at the 
methylation status of the APP gene, they found CpG island methylation at the APP promoter 
region of non- demented subjects, whilst there was a complete absence of DNA methylation 
in AD subjects. The hypomethylation of the APP gene could be one of the factors 
contributing to beta amyloid accumulation
162
. Furthermore, the regulation of tau 
phosphorylation is maintained by the equilibrium of activity of kinases and phosphatases. 
Abnormal tau hyperphosphorylation is a consequence of an imbalance of the activity of 
kinases and phosphotates, which may have resulted from aberrant DNA methylation
163;164
. 
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We also found that there was no relationship between global DNA methylation and Hcy 
levels (whether in the plasma or brain), and this lack of relationship was not altered when we 
included ApoE status in the analysis. A negative correlation between plasma Hcy levels and 
DNA methylation has previously been reported in a number of studies
53;165
; however results 
have not always been replicated
166-168
. Studies have shown that the effect of elevated Hcy 
levels on global DNA methylation is tissue-specific
108;169-171
. The lack of relationship between 
Hcy levels and global DNA methylation status was therefore not all together surprising, as 
other studies have shown very similar findings
168;170
. Heil and co-workers found that patients 
with cystationine beta-synthase (CBS) deficiency, which can result in a 30-fold increase in 
plasma Hcy, showed no alteration in global DNA methylation compared to subjects with no 
deficiency Furthermore, Brombery et al induced a 10-fold increase in plasma Hcy levels in 
mice and found no significant change in global DNA methylation in the frontal cortex
168;172
. 
These studies suggest that the lack of association between Hcy levels and global DNA 
methylation is due to the SAM/SAH ratio remaining constant even when there are 
considerable changes to the levels of Hcy, which may explain why the global DNA 
methylation status is preserved in our cohort even when Hcy levels are high.  
 
5.9. Effect of Homocysteine on the Cell Cycle 
 
We have used propidium iodide staining followed by cytometry to assess the cell cycle 
kinetics and cell numbers in our cultures. The LDH assay quantitatively measures cystosolic 
lactate dehydrogenase, which is released on cell lysis. This gave us a measure of the 
proportion of cells that died in our cultures prior to the completion of the experiments. By 
combining the data from the cytometry and LDH assay, we were able to calculate population 
doubling times and the length of the individual phases of the cell cycle.  
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With no ApoE added to the cultures, the cell numbers were found to significantly increase 
with increasing Hcy concentration, see Figure 43a. This mitogenic effect is consistent with 
previous studies that have shown that Hcy is able to induce proliferation in different cell 
types
133;166;173-175
. We found that population doubling times decreased with Hcy treatment (see 
Figure 43b): with the length of G1 and G2 time also decreasing proportionately. This 
indicates that Hcy can induce cell cycle entry allowing neuroblastomas to leave their retinoic 
acid induced differentiated state and begin to replicate their DNA. Cell proliferation and cell 
death where found to be discrepant at low doses of Hcy and parallel at higher doses, see 
Figure 43a.  Hcy is converted to cysteine through the transsulfuration pathway. Cysteine is an 
essential amino acid: Hcy treatment at normal physiological doses provides extra nutrition, 
which may drive cell proliferation. With increasing Hcy concentration cell death begins to 
increase, suggesting that Hcy becomes toxic at high doses. A number of studies have shown 
that high Hcy is associated with oxidative stress; this may be the trigger for apoptosis in our 
cultures 
166;176-178
.  
 
In the presence of ApoE2, there was a significant decrease in the number of cells with high 
dose Hcy treatment (>20µM), see Figure 44a. ApoE2 has a protective effect in differentiated 
neuroblastomas by inhibiting the proliferative effect of Hcy. The ‘protective’ influence of 
ApoE2 is lost at the highest Hcy concentration as the number of dead cells in the culture 
increased significantly. This indicates that ApoE2 cannot compensate for the effect of high 
dose Hcy on the cultured neuroblastomas, suggesting that ApoE2 is only protective at normal 
physiological concentrations of Hcy.   
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Unlike the ApoE2 isoform effect, in the presence of ApoE3 there was no change in cell 
numbers with increasing Hcy concentration. Furthermore, the number of dead cells remained 
stable at all Hcy doses, see Figure 45a. The length of the population doubling time decreased 
at high doses of Hcy (>20µM), showing that the inhibition of the Hcy-induced proliferative 
response was lost, see Figure 45b. This suggests that ApoE3 has more of a protective effect in 
the culture than ApoE2. ApoE3 is able to reduce the proliferative effect of Hcy and inhibit 
cell death.        
 
Similar to the ApoE3 treated cultures, the presence of ApoE4 inhibits the proliferative effect 
of Hcy (see Figure 46a). This may suggest that ApoE4 is protective. However, the population 
doubling time significantly decreased with Hcy treatment of above 5µM concentration, with 
the number of dead cells increasing significantly in a dose dependent manner (see Figure 46a 
and b). Even at physiologically normal levels of Hcy (10µM), ApoE4 could not compensate 
for the proliferative effect of Hcy.  
 
ApoE has been shown to have an anti-proliferative effect on a number of cell types
58;179
. From 
these studies, ApoE3 was shown to have the greatest anti-proliferative effect, which was also 
seen in our in vitro study. In AD, ApoE2 is considered protective: with the neuroprotective 
efficiency of ApoE2 greater than that of ApoE3
10;15;28;137
. This is not explained by our in vitro 
results or those of other studies
58;179
. However, it is difficult to compare the human brain to an 
in vitro model. Exogenous recombinant human ApoE may not be able to target all the 
signalling pathways that are targeted by endogenous ApoE. This would result in an altered 
neuroprotection efficiency of the ApoE isoforms in cell culture. Physiologically, the levels of 
ApoE4 in plasma are found to be much lower than the levels of ApoE2 and ApoE3
10
 in 
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plasma; however, in our culture model we used identical concentrations for all ApooE 
isoforms. Nevertheless, even with the levels of ApoE4 being the same as the other two 
isoforms, the effect of ApoE4 on protecting the cells against toxic levels of Hcy is still the 
lowest. This shows us that the influence of ApoE isoforms is not based on the relative amount 
of protein produced but on the functionality of the isoform.                
 
Adult neurones are considered to be in a quiescent state, in a similar way to the retinonic acid 
induced differentiated neuroblastomas. Cell cycle inhibitors keep neurones differentiated; 
however the cells retain their capacity to proliferate. It is only with a mitogenic stimuli and 
the loss of the cell cycle inhibitor effect that cells are able to re-enter the cell cycle. Aberrant 
cell cycle re-entry is thought to play a fundamental part in AD pathogenesis. The trigger for 
the proliferative response in the current in vitro study was shown to be high levels of Hcy. 
Hcy alone triggered proliferation in the differentiated neuroblastomas. The addition of any of 
the three ApoE isoforms to the culture seems to be protective, by reducing the rate of Hcy 
induced proliferation. The extent of the neuroprotection is ApoE isoform dependent. From our 
in vitro model, the ApoE3 seems to be most neuroprotective, and ApoE4 the least protective 
(ApoE3>ApoE2>ApoE4). This demonstrates that the Hcy-induced effect is modulated by 
ApoE in an ApoE isotype dependent manner.    
            
5.10. The Effect of Homocysteine on CDKI Methylation in Alzheimer’s Disease 
 
In the adult brain, neurones are in a differentiated state, but retain synaptic plasticity. In AD, 
the regions of the brain that are primarily affected by pathology are associated with a high 
degree of synaptic plasticity and higher cognitive functioning. It is therefore hypothesized that 
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in AD tightly controlled cell cycle regulation somehow fails during synaptic remodelling, and 
consequently neurones are allowed to re-enter the cell cycle and unable to revert back to their 
differentiated state.  
 
As explained in the previous chapter, some studies have shown that some genes are 
hypermethylated in cancer and that DNA methylation status of gene promoter regions can be 
altered and respond to changes in physiological conditions. We hypothesised that elevated 
Hcy levels cause aberrant DNA methylation of cell-cycle related genes, which may contribute 
to the failure of neuronal cell cycle control leading to the development of AD pathology.  
 
The cell cycle is a tightly controlled process. The progress of the cell through the different cell 
cycle phases is regulated by the activity of cyclin, cyclin-dependent kinases (CDKs) and 
cyclin-dependent kinases inhibitors (CDKIs). In the current study, we decided to investigate 
the DNA methylation status of the CDKI genes using DNA extracted from AD brain samples. 
We hypothesised that elevated Hcy levels result in hypermethylation of CpG islands on the 
CDKI gene promoter regions leading to aberrant cell cycle reactivation in neurones. 
 
5.10.1. AD Cohort 
 
We investigated the methylation status of five CDKI genes: p16
INK4a
, p15
INK4b
, p21
cip1
, p27
kip1
 
and p57
kip2 
in the lateral temporal lobe. We found that CDKI gene methylation did not relate 
to disease severity. Multiple regression analysis showed that hypermethylation of the p16
INK4a
 
gene was related to brain Hcy levels showing a positive relationship, whereas  
hypermethylation of the p16
INK4a
 gene related inversely to the brain Hcy/methionine ratio 
(close to significance, R
2
 = 0.29, p = 0.053). The relationship between brain Hcy and p16
INK4a 
gene
 
methylation was not dependent on the ApoE genotype. The methylation statuses of the 
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other CDKI genes were found to be independent of the Hcy concentration and the ApoE 
genotype (i.e. p15
INK4b
, p21
cip1
, p27
kip1
, p57
kip2
).  
 
p16
INK4a
 acts as a potent inhibitor of CDK4. Cyclin D1/CDK4 complex phosphorylates 
retinoblastoma protein (Rb). Rb is known to regulate the activity of a gene regulatory protein 
called E2F. Phosphorylation of Rb by cyclin/CDK complexes reduces the binding affinity of 
Rb to E2F, and E2F is free to activate S-phase related gene expression and further expression 
of cyclin D1 and CDK4. p16
INK4a 
protein inhibits the formation of  Cyclin D1/CDK4 
complexes and therefore inhibits cell cycle progression. Mutations in the p16
INK4a
 gene are 
rare. Studies have shown that downregulation of p16 is due to silencing of the p16
INK4a
 gene 
by DNA methylation
180-182
. Hypermethylation of the p16
INK4a
 gene promoter would alter p16 
protein expression and affect the balance between p16
 
and CDK4. In the current study we see 
that in AD brains p16
INK4a
 hypermethylation is associated with elevated brain Hcy levels. The 
increased amount of Hcy in the brain would indicate an imbalance in the folate cycle and 
changes in the methylation potential that could potentially lead to altered p16
INK4a 
promoter 
methylation.    
 
5.10.2. In Vitro study 
 
The changes in the population doubling times in the cultures are not associated with 
alterations of the cell cycle kinetics: all phases of the cell cycle were found to change equally. 
The changes to cell proliferation induced by Hcy and ApoE affect all phases of the cell cycle 
equally. Investigating the methylation status of CDKI genes would help us understand a 
possible mechanism by which Hcy may induce proliferation, and how this effect may be 
modulated by the different ApoE isoforms. Using our in vitro model we could confirm our 
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findings of CDKI gene methylation from the OPTIMA cohort. The custom-made SA 
Bioscience Methyl-Prolifer Arrays were also used for this part of the study, and the same 
CDKI genes were examined as for the OPTIMA cohort. Three treatments of Hcy were 
selected (5, 20 and 80µM) in the presence of either human recombinant ApoE3 or ApoE4 
isoform. 
 
p16
INK4a
 gene promoter methylation status analysis revealed a differential effect of Hcy in the 
presence of the different ApoE isoforms. With high dose Hcy treatment, in the presence of 
ApoE3, we see a decrease in the methylation status of the p16
INK4a
 promoter region, see 
Figure 55a. This suggests that ApoE3 may suppress the proliferative response triggered by 
Hcy, via hypomethylation of the p16
INK4a
 promoter, which leads to the upregulation of the 
p16
INK4a
 gene. When comparing the p16
INK4a
 methylation status to the cell cycle analysis data, 
we see that at 5 and 20µM of Hcy the population doubling slightly increases (see Figure 45b), 
suggesting that p16
INK4a
 hypomethylation has influenced cell proliferation and reduced cell 
death (see Figure 45a). At the highest dose, where p16
INK4a
 is hypomethylated population 
doubling times remain at baseline. This suggests that ApoE3 can inhibit the Hcy induced 
proliferation, by allowing p16
INK4a
 gene hypomethylation, which would increase expression 
of p16 protein to suppress G1 progression.  
 
With ApoE4 supplementation, there is increased p16
INK4a
 promoter hypermethylation with 
increasing Hcy concentration (see Figure 55a). p16
INK4a
 hypermethylation would lead to gene 
silencing and decrease in p16 protein expression. This in turn reduces the effect p16 has on 
inhibiting cell cycle re-entry. It seems that ApoE4 has less of an effect on inhibiting the Hcy 
induced proliferation, as p16
INK4a 
gene hypomethylation would allow cell cycle re-entry and 
G1 progression. From the cell numbers in ApoE4 treated cultures we see that the increase 
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hypermethylation of p16
INK4a
 is not accompanied by changes cell numbers (see Figure 46a). 
However, the hypermethylation of p16
INK4a
 is parallel to the increase in cell death seen in 
these cultures (see Figure 46a). This finding has been documented in other studies, including 
a study by Lau et al, where gene silencing of p16
INK4a
 by small interfering RNA (siRNA) did 
not alter cell proliferation. However, when the cells were put under UV-stress, increased 
apoptosis was seen in the siRNA treated cells
183
. This suggests that a relationship exists 
between elevated Hcy levels, p16
INK4a
 hypermethylation and increase cell death.
 
 
In the presence of ApoE3, no change in the p15
INK4b
 methylation status is seen. However, in 
the presence of ApoE4, the highest Hcy dose was found to significantly increase p15
INK4b
 
promoter methylation (from 0.02% to 0.45%), see Figure 55b. This suggests that at this dose 
the p15
INK4b
 promoter is highly methylated and may result in complete gene silencing. When 
looking at the cell cycle analysis of the ApoE4 cultures at 80µM of Hcy, we see a slight 
reduction in live cell numbers and high cell death when compared to the lower Hcy doses (see 
Figure 46a). This again suggests that hypermethylation, and subsequent gene silencing, of the 
INK family of CDKI genes is associated with cell death.      
 
Both p16
INK4a
 and p15
INK4b
 are inhibitors of CDK4 and CDK6. These CDKIs inhibit the 
interaction of CDK4/6 with cyclin D1, thereby preventing G1 progression. Both p16
INK4a
 and 
p15
INK4b
 show an increase in promoter methylation in the presence of ApoE4. When 
comparing p16
INK4a
 and p15
INK4b
 methylation in the presence of ApoE3 and ApoE4, we can 
see that ApoE4 is less effective at inhibiting promoter methylation compared to ApoE3, and 
that cells are more susceptible to G1 progression caused by Hcy in the presence of ApoE4.  
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The members of the cip/kip family of genes (i.e. p21
cip1
, p27
kip1
, and p57
kip2
) were grouped 
together, and the average methylation status of these genes examined (see Figure 56). The 
members of the cip/kip family of CDKI induce cell cycle arrest at the G1/S and G2/M 
checkpoints by inhibiting various cyclin/CDK complexes. p21 is up-regulated in response to 
activation of a tumor suppressor p53 by DNA damage and apoptosis. p21 inactivates CDK2, 
which forms complexes with cyclin A, cyclin D1 or cyclin E. Therefore p21 can inhibit 
several phases of the cell cycle and protect against DNA damage induced apoptosis
184
. p27 is 
highly expressed in quiescent cells: with expression declining once cells begin to 
proliferate
185
. Finally, p57 is imprinted by DNA methylation, where the paternal allele is 
transcriptionally repressed and the maternal allele is expressed
186
.  
 
We found that in the presence of ApoE3 the changes in cip/kip promoter methylation had a 
polynomial response to increasing Hcy concentrations. This effect is altered by ApoE4, such 
that significant alterations in methylation appear at lower Hcy concentrations and do not fall 
significantly as with the increasing Hcy concentrations. The methylation pattern of the cip/kip 
CDKI genes is parallel to the population doubling times in the cultures treated with ApoE and 
Hcy (see Figure 45, Figure 46 and Figure 55). 
     
5.11. The Effect of Homocysteine on CDKI protein expression 
 
Since CDKI expression is regulated at multiple levels, not just by promoter methylation, we 
regarded it important to assess the effect of Hcy on CDKI expression at the protein level. 
There was a trend showing an accumulation of p16 at the later stages of AD. The methylation 
status of the p16
INK4a 
gene did not relate to p16
 
protein expression. However, elevated levels 
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of brain Hcy were related to reduced expression of p16
 
protein in the occipital lobe (p = 
0.042). This relationship was not significantly affected by the ApoE genotype.           
 
Aging has been associated with increasing levels of p16
 
protein
187
.  Low levels of p16 have 
been found to significantly increase susceptibility to tumours
188
. There are well-documented 
changes in p16
 
protein expression in AD. p16
 
protein expression has been shown to be 
increased in brains of AD patients compared to aged match controls
108;189;190
. The increased 
p16 expression in late stages of AD appears contradictory to expectations if we accept the cell 
cycle hypothesis for the pathogenesis of AD. In theory, for neurones to re-enter the cell cycle 
and bypass the G1/S phase checkpoint you would expect reduced levels of p16 in the brain. 
However, the increased p16 immunoreactivity in the brain does not necessarily indicate 
increased p16 activity. It may only indicate an inappropriate accumulation of p16 where the 
neurones are attempting to abort the aberrant cell cycle activation.    
 
In the current study we see that elevated brain Hcy levels are associated with reduced p16 
immunoreactivity. Looking at the whole cohort we found that p16 protein immunoreactivity 
does not relate to the p16
INK4a
 methylation status. However, in patients with elevated brain 
Hcy levels, we found that the p16
INK4a
 promoter is hypermethylated, which in turn inhibits 
p16 protein production. This demonstrates that Hcy can induce aberrant gene methylation 
causing changes at the protein levels that would lead to cell cycle re-activation.           
 
Looking at the other CDKIs examined in this study, we found that p21 protein expression was 
not related to levels of Hcy or to the ApoE genotype. p27 and p57
 
expression in the occipital 
lobe were related to elevated levels of brain Hcy, and these relationships were ApoE4 
Chapter 4 Discussion 
 
154 
dependent. This increased expression of p27 and p57
 
could be due to an inappropriate 
accumulation of these CDKIs as the cell attempts to rescue itself from aberrant cell cycle 
activation. One further explanation could be that the increased expression of p27 and p57 
could potentially be an artifact, as tau is sticky and antibodies tend to bind to it. ApoE4 
carriers with elevated brain Hcy levels have shown accumulation of tau in the occipital lobe, 
the same region of the brain where both p27 and p57
 
proteins expression is increased. 
Although this may supports the notion that antibodies could be binding to tau rather than the 
CDKIs themselves, the use of highly specific antibodies reduces this risk to minimum.       
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6. CONCLUSION and FUTURE 
DIRECTIONS 
 
 
In conclusion, both our cohort analysis and the in vitro study demonstrate that Hcy affects the 
development of Alzheimer’s disease at multiple levels, cell cycle regulation, DNA 
methylation, induction of oxidative stress and direct effect on AD-type protein accumulation. 
These effects are modulated by the ApoE genotype. Our findings in the human brain are 
partially confirmed in our in vitro model. The discrepancies seen in the neuroblastoma 
cultures and the human brain are not wholly unexpected, as the findings in the brain reflect 
the long lasting exposure to elevated levels of Hcy while the cell culture model reflects the 
acute effects of relatively higher concentrations of Hcy. 
  
Our study provides a good starting point for the elucidation of the mechanistic molecular 
interactions between ApoE and Hcy in human disease. Further studies in human brains, 
animal model and cellular models of ageing and Alzheimer’s are needed to fully understand 
the interplay between these two risk factors for Alzheimer’s disease.       
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